TY 2022 Form 990

(A) Name and business address	(B) Description of services	(C) Compensation
WAVEACCESS USA 10161 WEST RUN PARK DRIVE SUITE 15 LAS VEGAS,NV89145	PROVIDE RESOURCES FOR BRAIN COMMONS AND	596,186
ICONIC EVENT STUDIOS INC 1861 SUNSET PLAZA DRIVE LOS ANGELES,CA90069	EVENT COORDINATION	477,417
HITACHI VANTARA LLC 2535 AUGUSTINE DRIVE SANTA CLARA,CA950543003	REAN AND BC	420,000
GRF CPA'S & ADVISORS 4550 MONTGOMERY AVENUE SUITE 800 N BETHESDA,MD20814	ACCOUNTING SERVICES	342,803
TONE CREATIVE LLC 63 PUTNAM STREET SUITE 202 SARASOTA SPRINGS,NY12866	MARKETING AND DESIGN SERVICES	273,270
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 20

- TIN:

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990) 2022

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..	20,795,052	16,316,026	16,160,581	17,941,055	10,755,381	81,968,095
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	20,795,052	16,316,026	16,160,581	17,941,055	10,755,381	81,968,095
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) ..						73,456,632
6	Public support. Subtract line 5 from line 4.						8,511,463

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
7	Amounts from line 4..	20,795,052	16,316,026	16,160,581	17,941,055	10,755,381	81,968,095
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	98,872	154,639	59,585	28,608	223,966	565,670
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..			32,104	112,735	364,187	509,026
11	Total support. Add lines 7 through 10						83,042,791

Gross receipts from related activities, etc. (see instructions) ..................

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 6, column (f) divided by line 11, column (f)) .........

10.250 %

Public support percentage for 2020 Schedule A, Part II, line 14 ...............

9.480 %

16a

33 1/3% support test—2022. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2021. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2022. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

10%-facts-and-circumstances test—2021. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990) 2022

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here................................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2021 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2022 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2021 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests-2022. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2021. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990) 2022

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990) 2022

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described on 11a above?

11b

A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described on line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a and 3b below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990) 2022

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990) 2022

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6 Other distributions (describe in Part VI). See instructions	6
7Total annual distributions. Add lines 1 through 6.	7
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	8
9 Distributable amount for 2022 from Section C, line 6	9
10 Line 8 amount divided by Line 9 amount	10

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2022	(iii) Distributable Amount for 2022
1 Distributable amount for 2022 from Section C, line 6
2 Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2022:
a From 2017.......
b From 2018.......
c From 2019.......
d From 2020.......
e From 2021.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2022 distributable amount
i Carryover from 2017 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2022 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2022 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2023. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2018.....
b Excess from 2019.....
c Excess from 2020.....
d Excess from 2021.....
e Excess from 2022.....

Schedule A (Form 990) (2022)

Schedule A (Form 990) 2022

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test
COHEN VETERANS BIOSCIENCE, INC. ("CVB") IS A PUBLIC CHARITY BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. WE ARE LEADING THE WAY TO CURE INVISIBLE WOUNDS FOR THE MILLIONS OF VETERANS, SERVICE MEMBERS, FIRST RESPONDERS, AND CIVILIANS WHO SUFFER FROM TRAUMA-RELATED CONDITIONS, SUCH AS PTSD, TBI AND SUICIDE. GLOBALLY, 2 BILLION INDIVIDUALS ARE DIRECTLY AFFECTED BY BRAIN DISORDERS. THE WORLD HEALTH ORGANIZATION ATTRIBUTES 38% OF THE TOTAL YEARS LOST TO DEATH AND DISABILITY TO BRAIN DISORDERS, A FIGURE WELL AHEAD OF THE NEXT-CLOSEST AND HIGHER-PROFILE DISEASES OF CANCER (12.7%) AND CARDIOVASCULAR DISEASE (11.8%). CVB IS CATALYZING RESEARCH TO ADVANCE BRAIN HEALTH AT ALL STAGES OF SCIENTIFIC DISCOVERY-FROM THEORY TO THERAPEUTIC.THIS MEMO PROVIDES EVIDENCE OF QUANTITATIVE AND QUALITATIVE MEASURES WHICH SUPPORT CONTINUED PUBLIC CHARITY STATUS. CVB MET THE QUANTITATIVE PERCENTAGE TEST CRITERION FOR SUPPORTING FACTS AND CIRCUMSTANCES IN FY23. CVB ENGAGES WITH AND MAKES AVAILABLE TO RESEARCHERS, POLICY MAKERS, AND THE GENERAL PUBLIC A BROAD ARRAY OF PROGRAMS, TOOLS, SERVICES, AND INFORMATION WHICH ADVANCE THE STATE OF BRAIN SCIENCE, GUIDED BY AN INDEPENDENT BOARD AND ADVISORY COUNSELS IN CONJUNCTION WITH CVB'S RENOWNED EXPERTS IN RELEVANT FIELDS OF NEUROSCIENCE, DATA SCIENCE AND PHARMACEUTICAL RESEARCH AND DEVELOPMENT. FOLLOWING ARE MORE DETAILED EVIDENCE OF THESE FACTS AND CIRCUMSTANCES. COHEN VETERANS BIOSCIENCE, INC. EARLY ORIGINS WERE AS AN ORGANIZATION UNDER THE FISCAL SPONSORSHIP OF THE MARIN COUNTY COMMUNITY FOUNDATION, LATER ESTABLISHED AS A STAND-ALONE 501(C)3 IN 2014 UNDER THE NAME ORION BIONETWORKS. CVB'S FOUNDER AND CEO HAS A PERSONAL CONNECTION TO THE PUBLIC WORK THE ORGANIZATION CARRIES OUT BY VIRTUE OF HER HUSBAND BEING A VETERAN OF THE US AIRFORCE SERVICE AND HER SISTER SERVING AS AN AIRFORCE COLONEL, WITH ACTIVE DEPLOYMENTS TO OEF/OIF. THE FORMAL NAME CHANGE TO COHEN VETERANS BIOSCIENCE TOOK PLACE IN 2015 IN CONCERT WITH GENEROUS SEED FUNDING FROM STEVEN A. COHEN. CVB QUALIFIES AS A PUBLIC CHARITY UNDER THE "FACTS AND CIRCUMSTANCES" TEST OF 1.170A-9(F)(3) OF THE TREASURY REGULATIONS, BASED UPON THE FOLLOWING:CVB IS ORGANIZED AND OPERATED SO AS TO ATTRACT NEW AND ADDITIONAL FUNDING ON A CONTINUOUS AND BONA FIDE BASIS; CVB'S CURRENT FUNDRAISING PLANS ARE TARGETED AT A BROAD BASE OF DONORS, INCLUDING FOUNDATIONS, INDIVIDUALS, AND GOVERNMENT AGENCIES. - ONLINE GIVING: CVB HAS HAD A DONATION BUTTON ON ITS WEBSITE AND ALL SOCIAL MEDIA SINCE INCEPTION. AS OF FY22, WE ESTABLISHED REGISTERED STATUS ACROSS ALL 50 STATES. THE ORGANIZATION RUNS SEVERAL ONLINE DONATION CAMPAIGNS THROUGHOUT THE YEAR (E.G. MEMORIAL DAY, VETERANS DAY, GIVING DAY). -FUNDRAISING EVENTS: WE CONTINUE TO GROW OUR REACH TO THE GENERAL PUBLIC THROUGH FUNDRAISING EVENTS, SOME SPONSORED DIRECTLY AND OTHERS ON OUR BEHALF THROUGH OUR AMBASSADOR'S PROGRAM AND ALSO A CROWDRISE CAMPAIGN CAPABILITY WE ADDED TO OUR WEBSITE IN FY23. STARTING IN 2020, WE ENGAGED IN PARTNERSHIPS WITH VETERANS SERVICE ORGANIZATIONS WHO HAVE COMMITTED TO RAISE AWARENESS OF INDIVIDUALLY DRIVEN FUNDRAISING CAMPAIGNS FOR VETERANS PTSD, TBI AND SUICIDE.-MEMBERSHIP PROGRAMS: -IN 2022, WE LAUNCHED AN ANNUAL MEMBERSHIP PROGRAM WITH OTHER NONPROFIT FOUNDATIONS, UNDER OUR COALITION TO HEAL INVISIBLE WOUNDS, TO SUPPORT ADVOCACY AND EDUCATION INITIATIVES. -IN 2023, WE LAUNCHED THE TBI ACTION ALLIANCE PROGRAM WHICH INCLUDES BOTH MEMBERSHIP AND SPONSORSHIP OPPORTUNITIES FOR INDIVIDUALS, PROFESSIONALS, AND INSTITUTIONS TO SUPPORT OUR RESEARCH PROGRAMS TO ADVANCE DIAGNOSTICS AND THERAPEUTICS FOR TRAUMATIC BRAIN INJURIES (TBI). WE HAVE OVER 50 MEMBERS AND INSTITUTIONS ENROLLED TO DATE.-GOVERNMENT & FOUNDATION RESEARCH GRANTS: CVB HAS RECEIVED SUPPORT US GOVERNMENT AGENCIES SUCH AS THE NATIONAL INSTITUTES OF HEALTH AND THE DEPARTMENT OF DEFENSE; A NUMBER OF NONPROFIT ORGANIZATIONS AND FOUNDATIONS INTERESTED IN MEDICAL RESEARCH AND ISSUES IMPACTING VETERANS.AS EVIDENCED BY THE EXTENSIVE PROGRAMS SPONSORED BY CVB SUPPORTING RESEARCH COLLABORATIONS AND SCIENTIFIC BEST PRACTICE ADOPTION, CVB REMAINS AN ORGANIZATION COMMITTED TO SERVING THE PUBLIC THROUGH ITS WORK. EXAMPLES WHICH DEMONSTRATE OUR COMMITMENT TO THE PUBLIC BENEFIT AND PUBLIC PARTICIPATION IN OUR EFFORTS INCLUDE CVB'S VETERANS ADVISORY COUNCIL, STATE OF THE SCIENCE SUMMITS, NUMEROUS EXPERT WORKSHOPS, ENSURING OUR RESEARCH IS PUBLISHED IN OPEN ACCESS PUBLICATIONS, AND DATA SHARING POLICIES ENCOURAGING RESEARCH COLLABORATION ACROSS ORGANIZATIONAL BOUNDARIES. CVB PROGRAM ACTIVITIES, WITH TEAM SCIENCE AND COLLABORATION AS A CORE BELIEF, PROVIDES DIRECT PUBLIC BENEFIT THROUGH ITS RESEARCH AND EDUCATIONAL ACTIVITIES. CVB SPEARHEADS RESEARCH WITH MULTI-SECTOR PARTNERS INCLUDING ACADEMIA, GOVERNMENT, FOUNDATION RESEARCH, AND INDUSTRY ORGANIZATIONS TO ADVANCE COLLECTIVE UNDERSTANDING OF AND APPROACHES TO IMPROVING BRAIN HEALTH. FOR EXAMPLE, CVB SPONSORED THE BRAIN TRAUMA BLUEPRINT IN PARTNERSHIP WITH THE VETERANS ADMINISTRATION, NATIONAL INSTITUTES OF HEALTH AND DEPARTMENT OF DEFENSE TO ESTABLISH A RESEARCH ROADMAP FOR THE ADVANCEMENT OF PRECISION THERAPEUTIC SOLUTIONS FOR TRAUMATIC BRAIN INJURY (HTTPS://WWW.BRAINTRAUMABLUEPRINT.ORG/). CVB ALSO BROADLY DISSEMINATES RESEARCH AND EDUCATIONAL INFORMATION ABOUT PTSD, TRAUMATIC BRAIN INJURY (TBI) AND SUICIDE DIRECTLY TO THE PUBLIC THROUGH ITS WEBSITE AND SOCIAL MEDIA. THE INFORMATION IS PROVIDED IN AN ACCESSIBLE AND UNDERSTANDABLE FORMAT FOR ANY NON-MEDICAL READER, HELPING VETERANS AND OTHERS SUFFERING FROM PTSD OR TBI TO UNDERSTAND THEIR CONDITIONS AND THE SYMPTOMS AND CAUSES ASSOCIATED WITH THEM. THESE MATERIALS ALSO SERVE TO EDUCATE THE PUBLIC ABOUT PTSD AND TBI AND THE EFFECTS OF THESE CONDITIONS ON OUR VETERANS AND FAMILIES. THESE EVENTS, PROCEEDINGS, AND OTHER EDUCATIONAL OUTREACH SERVE TO ADVANCE BRAIN SCIENCE IN THE PUBLIC INTEREST. SEE WWW.COHENVETERANSBIOSCIENCE.ORG AND THE FORM 990 PROGRAM DESCRIPTIONS FOR MORE DETAILS ON THE EXPANSIVE NATURE OF THESE PROGRAMS. CVB ALSO ENLISTS THE ACTIVE SUPPORT AND PARTICIPATION OF EXPERTS, PUBLIC OFFICIALS, AND COMMUNITY LEADERS. CVB'S VETERANS ADVISORY COUNCIL ("VAC") INCLUDES SENIOR LEADERS WHO SERVED IN MILITARY LEADERSHIP ROLES AND/OR HAVE VETERAN FAMILY MEMBERS AND HAVE A DEEP PERSONAL COMMITMENT TO VETERANS' CONCERNS RELATED TO BRAIN HEALTH. VAC HELPS REPRESENT, ADVOCATE AND SUPPORT MILITARY AND VETERANS' INTERESTS TO CVB TO AID CVB IN DELIVERING MEANINGFUL RESULTS FOR VETERANS THROUGH DATA-DRIVEN SCIENCE AND ADVOCACY. MORE INFORMATION ABOUT VAC IS AVAILABLE HERE: HTTPS://WWW.COHENVETERANSBIOSCIENCE.ORG/VETERANS-ADVISORY-COUNCIL/ IN 2020, CVB EXPANDED ITS GLOBAL FOOTPRINT BY FORGING A PARTNERSHIP WITH THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY TO ESTABLISH THE GLOBAL PRECLINICAL DATA FORUM, IN SUPPORT OF REPRODUCIBLE RESEARCH EFFORTS (HTTPS://WWW.PRECLINICALDATAFORUM.ORG/). CVB ALSO JOINED THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS TO CO-SPONSOR RESEARCH WITH THE INNOVATIVE MEDICINES INITIATIVE (HTTPS://WWW.IMI.EUROPA.EU/PROJECTS-RESULTS/PROJECT-FACTSHEETS/PRISM-2) AT AN INTERNATIONAL LEVEL. IN 2022, WE HAVE EXPANDED THESE INTERNATIONAL PARTNERSHIPS THROUGH THE ESTABLISHMENT OF OUR BRAIN HEALTH NEXUS PROGRAM THAT ENGAGES LEADERS FROM THE WORLD HEALTH ORGANIZATION, OECD, EUROPEAN BRAIN COUNCIL, CANADIAN AND UK ORGANIZATIONS. IN 2023, WE RECEIVED MAJOR FUNDING FROM THE CANADIAN ONTARIO BRAIN INSTITUTE IN SUPPORT OF OUR BRAIN HEALTH INITIATIVES.FINALLY, CVB HAS A REPRESENTATIVE GOVERNING BODY THROUGH ITS UNCOMPENSATED BOARD OF DIRECTORS CONSISTING OF FOUR MEMBERS WITH EQUAL VOTING RIGHTS. THREE OF THE FOUR MEMBERS ARE INDEPENDENT OF THE LARGEST DONOR. ALL OF THE BOARD MEMBERS ARE INDIVIDUALS WITH SPECIAL KNOWLEDGE AND EXPERTISE RELEVANT TO THE ORGANIZATION'S CHARITABLE ACTIVITIES IN BRAIN SCIENCE AND HEALTH, AS WELL AS MEMBERS WITH LONGSTANDING DEDICATION TO THE NEEDS OF VETERANS AND OTHERS WHO SUFFER FROM BRAIN DISEASES THROUGH BOTH PAID AND UNPAID WORK WITH GOVERNMENT AND OTHER NONPROFIT AGENCIES. THE QUALIFICATIONS OF THE BOARD MEMBERS INCLUDE:BOARD CHAIR AND CEO, MAGALI HAAS, MD, PHD FOUNDED ORION BIONETWORKS (RENAMED TO COHEN VETERANS BIOSCIENCE IN 2015) WITH SPONSORSHIP FROM JANSSEN RESEARCH & DEVELOPMENT TO UNLOCK THE POWER OF SHARED DATA AND PREDICTIVE MODELING TO HELP TRANSFORM OUR UNDERSTANDING OF BRAIN DISEASES AND ACCELERATE THE SEARCH FOR CURES.

Facts And Circumstances Test

COHEN VETERANS BIOSCIENCE, INC. ("CVB") IS A PUBLIC CHARITY BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. WE ARE LEADING THE WAY TO CURE INVISIBLE WOUNDS FOR THE MILLIONS OF VETERANS, SERVICE MEMBERS, FIRST RESPONDERS, AND CIVILIANS WHO SUFFER FROM TRAUMA-RELATED CONDITIONS, SUCH AS PTSD, TBI AND SUICIDE. GLOBALLY, 2 BILLION INDIVIDUALS ARE DIRECTLY AFFECTED BY BRAIN DISORDERS. THE WORLD HEALTH ORGANIZATION ATTRIBUTES 38% OF THE TOTAL YEARS LOST TO DEATH AND DISABILITY TO BRAIN DISORDERS, A FIGURE WELL AHEAD OF THE NEXT-CLOSEST AND HIGHER-PROFILE DISEASES OF CANCER (12.7%) AND CARDIOVASCULAR DISEASE (11.8%). CVB IS CATALYZING RESEARCH TO ADVANCE BRAIN HEALTH AT ALL STAGES OF SCIENTIFIC DISCOVERY-FROM THEORY TO THERAPEUTIC.THIS MEMO PROVIDES EVIDENCE OF QUANTITATIVE AND QUALITATIVE MEASURES WHICH SUPPORT CONTINUED PUBLIC CHARITY STATUS. CVB MET THE QUANTITATIVE PERCENTAGE TEST CRITERION FOR SUPPORTING FACTS AND CIRCUMSTANCES IN FY23. CVB ENGAGES WITH AND MAKES AVAILABLE TO RESEARCHERS, POLICY MAKERS, AND THE GENERAL PUBLIC A BROAD ARRAY OF PROGRAMS, TOOLS, SERVICES, AND INFORMATION WHICH ADVANCE THE STATE OF BRAIN SCIENCE, GUIDED BY AN INDEPENDENT BOARD AND ADVISORY COUNSELS IN CONJUNCTION WITH CVB'S RENOWNED EXPERTS IN RELEVANT FIELDS OF NEUROSCIENCE, DATA SCIENCE AND PHARMACEUTICAL RESEARCH AND DEVELOPMENT. FOLLOWING ARE MORE DETAILED EVIDENCE OF THESE FACTS AND CIRCUMSTANCES. COHEN VETERANS BIOSCIENCE, INC. EARLY ORIGINS WERE AS AN ORGANIZATION UNDER THE FISCAL SPONSORSHIP OF THE MARIN COUNTY COMMUNITY FOUNDATION, LATER ESTABLISHED AS A STAND-ALONE 501(C)3 IN 2014 UNDER THE NAME ORION BIONETWORKS. CVB'S FOUNDER AND CEO HAS A PERSONAL CONNECTION TO THE PUBLIC WORK THE ORGANIZATION CARRIES OUT BY VIRTUE OF HER HUSBAND BEING A VETERAN OF THE US AIRFORCE SERVICE AND HER SISTER SERVING AS AN AIRFORCE COLONEL, WITH ACTIVE DEPLOYMENTS TO OEF/OIF. THE FORMAL NAME CHANGE TO COHEN VETERANS BIOSCIENCE TOOK PLACE IN 2015 IN CONCERT WITH GENEROUS SEED FUNDING FROM STEVEN A. COHEN. CVB QUALIFIES AS A PUBLIC CHARITY UNDER THE "FACTS AND CIRCUMSTANCES" TEST OF 1.170A-9(F)(3) OF THE TREASURY REGULATIONS, BASED UPON THE FOLLOWING:CVB IS ORGANIZED AND OPERATED SO AS TO ATTRACT NEW AND ADDITIONAL FUNDING ON A CONTINUOUS AND BONA FIDE BASIS; CVB'S CURRENT FUNDRAISING PLANS ARE TARGETED AT A BROAD BASE OF DONORS, INCLUDING FOUNDATIONS, INDIVIDUALS, AND GOVERNMENT AGENCIES. - ONLINE GIVING: CVB HAS HAD A DONATION BUTTON ON ITS WEBSITE AND ALL SOCIAL MEDIA SINCE INCEPTION. AS OF FY22, WE ESTABLISHED REGISTERED STATUS ACROSS ALL 50 STATES. THE ORGANIZATION RUNS SEVERAL ONLINE DONATION CAMPAIGNS THROUGHOUT THE YEAR (E.G. MEMORIAL DAY, VETERANS DAY, GIVING DAY). -FUNDRAISING EVENTS: WE CONTINUE TO GROW OUR REACH TO THE GENERAL PUBLIC THROUGH FUNDRAISING EVENTS, SOME SPONSORED DIRECTLY AND OTHERS ON OUR BEHALF THROUGH OUR AMBASSADOR'S PROGRAM AND ALSO A CROWDRISE CAMPAIGN CAPABILITY WE ADDED TO OUR WEBSITE IN FY23. STARTING IN 2020, WE ENGAGED IN PARTNERSHIPS WITH VETERANS SERVICE ORGANIZATIONS WHO HAVE COMMITTED TO RAISE AWARENESS OF INDIVIDUALLY DRIVEN FUNDRAISING CAMPAIGNS FOR VETERANS PTSD, TBI AND SUICIDE.-MEMBERSHIP PROGRAMS: -IN 2022, WE LAUNCHED AN ANNUAL MEMBERSHIP PROGRAM WITH OTHER NONPROFIT FOUNDATIONS, UNDER OUR COALITION TO HEAL INVISIBLE WOUNDS, TO SUPPORT ADVOCACY AND EDUCATION INITIATIVES. -IN 2023, WE LAUNCHED THE TBI ACTION ALLIANCE PROGRAM WHICH INCLUDES BOTH MEMBERSHIP AND SPONSORSHIP OPPORTUNITIES FOR INDIVIDUALS, PROFESSIONALS, AND INSTITUTIONS TO SUPPORT OUR RESEARCH PROGRAMS TO ADVANCE DIAGNOSTICS AND THERAPEUTICS FOR TRAUMATIC BRAIN INJURIES (TBI). WE HAVE OVER 50 MEMBERS AND INSTITUTIONS ENROLLED TO DATE.-GOVERNMENT & FOUNDATION RESEARCH GRANTS: CVB HAS RECEIVED SUPPORT US GOVERNMENT AGENCIES SUCH AS THE NATIONAL INSTITUTES OF HEALTH AND THE DEPARTMENT OF DEFENSE; A NUMBER OF NONPROFIT ORGANIZATIONS AND FOUNDATIONS INTERESTED IN MEDICAL RESEARCH AND ISSUES IMPACTING VETERANS.AS EVIDENCED BY THE EXTENSIVE PROGRAMS SPONSORED BY CVB SUPPORTING RESEARCH COLLABORATIONS AND SCIENTIFIC BEST PRACTICE ADOPTION, CVB REMAINS AN ORGANIZATION COMMITTED TO SERVING THE PUBLIC THROUGH ITS WORK. EXAMPLES WHICH DEMONSTRATE OUR COMMITMENT TO THE PUBLIC BENEFIT AND PUBLIC PARTICIPATION IN OUR EFFORTS INCLUDE CVB'S VETERANS ADVISORY COUNCIL, STATE OF THE SCIENCE SUMMITS, NUMEROUS EXPERT WORKSHOPS, ENSURING OUR RESEARCH IS PUBLISHED IN OPEN ACCESS PUBLICATIONS, AND DATA SHARING POLICIES ENCOURAGING RESEARCH COLLABORATION ACROSS ORGANIZATIONAL BOUNDARIES. CVB PROGRAM ACTIVITIES, WITH TEAM SCIENCE AND COLLABORATION AS A CORE BELIEF, PROVIDES DIRECT PUBLIC BENEFIT THROUGH ITS RESEARCH AND EDUCATIONAL ACTIVITIES. CVB SPEARHEADS RESEARCH WITH MULTI-SECTOR PARTNERS INCLUDING ACADEMIA, GOVERNMENT, FOUNDATION RESEARCH, AND INDUSTRY ORGANIZATIONS TO ADVANCE COLLECTIVE UNDERSTANDING OF AND APPROACHES TO IMPROVING BRAIN HEALTH. FOR EXAMPLE, CVB SPONSORED THE BRAIN TRAUMA BLUEPRINT IN PARTNERSHIP WITH THE VETERANS ADMINISTRATION, NATIONAL INSTITUTES OF HEALTH AND DEPARTMENT OF DEFENSE TO ESTABLISH A RESEARCH ROADMAP FOR THE ADVANCEMENT OF PRECISION THERAPEUTIC SOLUTIONS FOR TRAUMATIC BRAIN INJURY (HTTPS://WWW.BRAINTRAUMABLUEPRINT.ORG/). CVB ALSO BROADLY DISSEMINATES RESEARCH AND EDUCATIONAL INFORMATION ABOUT PTSD, TRAUMATIC BRAIN INJURY (TBI) AND SUICIDE DIRECTLY TO THE PUBLIC THROUGH ITS WEBSITE AND SOCIAL MEDIA. THE INFORMATION IS PROVIDED IN AN ACCESSIBLE AND UNDERSTANDABLE FORMAT FOR ANY NON-MEDICAL READER, HELPING VETERANS AND OTHERS SUFFERING FROM PTSD OR TBI TO UNDERSTAND THEIR CONDITIONS AND THE SYMPTOMS AND CAUSES ASSOCIATED WITH THEM. THESE MATERIALS ALSO SERVE TO EDUCATE THE PUBLIC ABOUT PTSD AND TBI AND THE EFFECTS OF THESE CONDITIONS ON OUR VETERANS AND FAMILIES. THESE EVENTS, PROCEEDINGS, AND OTHER EDUCATIONAL OUTREACH SERVE TO ADVANCE BRAIN SCIENCE IN THE PUBLIC INTEREST. SEE WWW.COHENVETERANSBIOSCIENCE.ORG AND THE FORM 990 PROGRAM DESCRIPTIONS FOR MORE DETAILS ON THE EXPANSIVE NATURE OF THESE PROGRAMS. CVB ALSO ENLISTS THE ACTIVE SUPPORT AND PARTICIPATION OF EXPERTS, PUBLIC OFFICIALS, AND COMMUNITY LEADERS. CVB'S VETERANS ADVISORY COUNCIL ("VAC") INCLUDES SENIOR LEADERS WHO SERVED IN MILITARY LEADERSHIP ROLES AND/OR HAVE VETERAN FAMILY MEMBERS AND HAVE A DEEP PERSONAL COMMITMENT TO VETERANS' CONCERNS RELATED TO BRAIN HEALTH. VAC HELPS REPRESENT, ADVOCATE AND SUPPORT MILITARY AND VETERANS' INTERESTS TO CVB TO AID CVB IN DELIVERING MEANINGFUL RESULTS FOR VETERANS THROUGH DATA-DRIVEN SCIENCE AND ADVOCACY. MORE INFORMATION ABOUT VAC IS AVAILABLE HERE: HTTPS://WWW.COHENVETERANSBIOSCIENCE.ORG/VETERANS-ADVISORY-COUNCIL/ IN 2020, CVB EXPANDED ITS GLOBAL FOOTPRINT BY FORGING A PARTNERSHIP WITH THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY TO ESTABLISH THE GLOBAL PRECLINICAL DATA FORUM, IN SUPPORT OF REPRODUCIBLE RESEARCH EFFORTS (HTTPS://WWW.PRECLINICALDATAFORUM.ORG/). CVB ALSO JOINED THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS TO CO-SPONSOR RESEARCH WITH THE INNOVATIVE MEDICINES INITIATIVE (HTTPS://WWW.IMI.EUROPA.EU/PROJECTS-RESULTS/PROJECT-FACTSHEETS/PRISM-2) AT AN INTERNATIONAL LEVEL. IN 2022, WE HAVE EXPANDED THESE INTERNATIONAL PARTNERSHIPS THROUGH THE ESTABLISHMENT OF OUR BRAIN HEALTH NEXUS PROGRAM THAT ENGAGES LEADERS FROM THE WORLD HEALTH ORGANIZATION, OECD, EUROPEAN BRAIN COUNCIL, CANADIAN AND UK ORGANIZATIONS. IN 2023, WE RECEIVED MAJOR FUNDING FROM THE CANADIAN ONTARIO BRAIN INSTITUTE IN SUPPORT OF OUR BRAIN HEALTH INITIATIVES.FINALLY, CVB HAS A REPRESENTATIVE GOVERNING BODY THROUGH ITS UNCOMPENSATED BOARD OF DIRECTORS CONSISTING OF FOUR MEMBERS WITH EQUAL VOTING RIGHTS. THREE OF THE FOUR MEMBERS ARE INDEPENDENT OF THE LARGEST DONOR. ALL OF THE BOARD MEMBERS ARE INDIVIDUALS WITH SPECIAL KNOWLEDGE AND EXPERTISE RELEVANT TO THE ORGANIZATION'S CHARITABLE ACTIVITIES IN BRAIN SCIENCE AND HEALTH, AS WELL AS MEMBERS WITH LONGSTANDING DEDICATION TO THE NEEDS OF VETERANS AND OTHERS WHO SUFFER FROM BRAIN DISEASES THROUGH BOTH PAID AND UNPAID WORK WITH GOVERNMENT AND OTHER NONPROFIT AGENCIES. THE QUALIFICATIONS OF THE BOARD MEMBERS INCLUDE:BOARD CHAIR AND CEO, MAGALI HAAS, MD, PHD FOUNDED ORION BIONETWORKS (RENAMED TO COHEN VETERANS BIOSCIENCE IN 2015) WITH SPONSORSHIP FROM JANSSEN RESEARCH & DEVELOPMENT TO UNLOCK THE POWER OF SHARED DATA AND PREDICTIVE MODELING TO HELP TRANSFORM OUR UNDERSTANDING OF BRAIN DISEASES AND ACCELERATE THE SEARCH FOR CURES.

Return Reference	Explanation
SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:	HRA FORFEITURES - 2020 AMOUNT: $ 28,475. STIMULUS/COVID CREDITS - 2020 AMOUNT: $ 3,629. 2021 AMOUNT: $ 2,480. OTHER REFUNDS - 2021 AMOUNT: $ 110,255. OTHER INCOME - 2022 AMOUNT: $ 37,205. GRANT REFUNDS - 2022 AMOUNT: $ 326,982.
PART II SECT C LINE 17A FACTS & CIRCUMSTANCES TEST (CONT):	DR. HAAS HAS OVER 20 YEARS OF PHARMACEUTICAL EXECUTIVE AND CLINICAL RESEARCH EXPERIENCE INCLUDING DEVELOPMENT LEADERSHIP ROLES IN MEDICAL MARKETING, FULL CLINICAL DEVELOPMENT, EARLY DEVELOPMENT, AND TRANSLATIONAL AND BIOMARKER SCIENCES IN PSYCHIATRY AND NEUROLOGY. DURING HER TENURE AT JOHNSON & JOHNSON, SHE SUCCESSFULLY FILED NDAS IN THE US AND EUROPE FOR RISPERIDONE INDICATIONS IN AUTISM, ADOLESCENT SCHIZOPHRENIA, JUVENILE BIPOLAR DISORDER AND CONDUCT DISORDERS. SHE ALSO LED DEVELOPMENT TEAMS EVALUATING COMPOUNDS FOR DEPRESSION, NEUROPATHIC PAIN, EPILEPSY, AND MIGRAINE DISORDER. SHE SERVED 3 YEARS AS CHIEF SCIENCE AND TECHNOLOGY OFFICER FOR ONE MIND FOR RESEARCH, A NONPROFIT ORGANIZATION LAUNCHED IN MAY 2012 BY PATRICK J KENNEDY. SHE ORCHESTRATED THE LAUNCH OF ONE MIND'S SEMINAL PROGRAMS, APOLLO, AN INFORMATICS RESEARCH PORTAL AND, GEMINI, AN INTERNATIONAL TBI/PTSD RESEARCH PROGRAM. AS AN "INTRAPRENEUR" AT J&J SHE ESTABLISHED THE FIRST NEUROSCIENCE TRANSLATIONAL MEDICINE & INTEGRATIVE SOLUTIONS DEPARTMENT, AND CO-FOUNDED THE FIRST COMPANION DIAGNOSTICS CENTER OF EXCELLENCE AS WELL AS J&J'S HEALTHCARE INNOVATION TEAM. SHE SERVES ON SEVERAL ADVISORY BOARDS INCLUDING ALTO NEUROSCIENCE, KREMBIL CENTRE FOR NEUROINFORMATICS, VIRTUALBRAINCLOUD, PARTNERSHIP FOR ASSESSMENT AND ACCREDITATION OF SCIENTIFIC PRACTICE (PAASP) AND INTERUNIVERSITY MICROELECTRONICS CENTRE (IMEC) AN INTERNATIONAL RESEARCH & DEVELOPMENT AND INNOVATION HUB. DR. HAAS EARNED HER BS IN BIOENGINEERING FROM THE UNIVERSITY OF PENNSYLVANIA, AN MS IN BIOMEDICAL ENGINEERING FROM RUTGERS UNIVERSITY, NEW JERSEY, AND HER MD PHD WITH DISTINCTION IN NEUROSCIENCE FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, NEW YORK. BOARD MEMBER, SECRETARY, THERESA FRANGIOSA HAS EXTENSIVE EXECUTIVE EXPERIENCED BASED ON HER 25 YEAR CAREER WITH THE PHARMACEUTICAL SECTOR. IN HER ROLES WITHIN PHARMA, SHE WAS A GLOBAL LAUNCH LEADER AS WELL AS OVERSEEING EARLY COMMERCIAL STRATEGY IN NEUROSCIENCES. SHE LED LARGE SCALE TEAMS, CROSS-FUNCTIONAL TEAMS TO DEFINE DISEASE AND THERAPEUTIC AREA STRATEGIES FOR JANSSEN AND GLAXOSMITHKLINE. SHE HAS ALSO LED INDICATION PRIORITIZATION EFFORTS AND DEVELOPMENT OF OVER 200 TARGET PRODUCT PROFILES OVER A VARIETY OF DISEASE STATES, LEVERAGING WELL-ESTABLISHED PROCESSES AND FRAMEWORKS, INCLUDING DEEPER UNDERSTANDING OF PATIENT JOURNEYS TO CREATE KEY INSIGHTS. SHE HAS APPLIED HER PROFESSIONAL CAREER EXPERIENCE AND HER PASSION FOR ADVOCACY TO HELP CREATE A CHANNEL FOR FEEDBACK FROM THOSE DIAGNOSED WITH OR AT RISK FOR ALZHEIMER'S DISEASE OR DEMENTIA, THEIR CARE PARTNERS AND INDIVIDUALS WHO ARE 'WORRIED WELL', CALLED THE A-LIST. SHE IS THE LEAD INVESTIGATOR FOR THIS RESEARCH STUDY WITH IRB OVERSIGHT. MS. FRANGIOSA OBTAINED HER BACHELOR OF ADMINISTRATION, ACCOUNTING CONCENTRATION FROM URSINUS COLLEGE (COLLEGEVILLE, PA) IN 1988 AND HER MASTERS OF BUSINESS ADMINISTRATION, PHARMACEUTICAL MARKETING FROM ST. JOSEPH'S UNIVERSITY IN 1996. BOARD MEMBER, TREASURER, MICHAEL C. SULLIVAN IS THE CHIEF OF STAFF AND HEAD OF EXTERNAL AFFAIRS OF POINT72 ASSET MANAGEMENT. MR. SULLIVAN PREVIOUSLY SERVED AS A SENIOR AIDE IN THE UNITED STATES SENATE, FOCUSING ON TELECOM, TECHNOLOGY, AND FINANCE ISSUES. MR. SULLIVAN ALSO SERVED AS A STAFF MEMBER IN THE U.S. HOUSE OF REPRESENTATIVES WORKING ON SIMILAR ISSUES. BEFORE COMING TO CAPITOL HILL, MR. SULLIVAN WAS THE HEAD OF STRATEGIC DEVELOPMENT FOR A TELECOMMUNICATIONS FOCUSED TRADE ASSOCIATION. MR. SULLIVAN IS INVOLVED WITH SEVERAL VETERANS' MENTAL HEALTH-RELATED NONPROFIT ORGANIZATIONS. HE HELPED ESTABLISH AND SERVES ON THE BOARD AND AS TREASURER OF THE COHEN VETERANS NETWORK, WHICH OPERATES A NATIONAL NETWORK OF CLINICS TO TREAT VETERANS AND THEIR FAMILY MEMBERS AFFECTED BY POST-TRAUMATIC STRESS. MR. SULLIVAN IS AN ASSOCIATE AT THE NYU-STERN ENDLESS FRONTIER LABS, WHERE HE MENTORS START-UP COMPANIES IN ARTIFICIAL INTELLIGENCE, MACHINE LEARNING, AND RELATED FIELDS. HE IS ALSO A MEMBER OF THE EXECUTIVE COMMITTEE OF STUDENTS FIRST NEW YORK, A NONPROFIT ORGANIZATION ADVOCATING FOR EDUCATIONAL REFORM IN NEW YORK STATE. MR. SULLIVAN IS A GRADUATE OF VANDERBILT UNIVERSITY. BOARD MEMBER, DAVID BIONDI, MD HAS OVER 20 YEARS OF CLINICAL EXPERIENCE IN MEDICAL PRACTICE AND HELD MEDICAL DIRECTORSHIPS AT THE US NAVAL HOSPITAL IN OKINAWA JAPAN, THE PAIN MANAGEMENT PROGRAM & HEADACHE INSTITUTE AT MARYVIEW MEDICAL CENTER IN PORTSMOUTH VA, THE PAIN DIVISION OF THE MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE IN ANN ARBOR MI, AND THE INTERDISCIPLINARY HEADACHE & PAIN REHABILITATION PROGRAM AT SPAULDING REHABILITATION HOSPITAL IN BOSTON MA. HE WAS PREVIOUSLY AN ASSISTANT NEUROLOGIST AT THE MASSACHUSETTS GENERAL HOSPITAL AND AN INSTRUCTOR IN NEUROLOGY AT HARVARD MEDICAL SCHOOL. DR. BIONDI SERVED AS A TRUSTEE FOR THE UNIVERSITY OF NEW ENGLAND AND WAS CHAIR OF ITS ACADEMIC AND RESEARCH AFFAIRS COMMITTEE AND VICE-CHAIR OF ITS LONG-RANGE PLANNING COMMITTEE. HE ALSO SERVED AS A DIRECTOR AND MEDICAL ADVISOR FOR THE AFTER ACTION NETWORK, A NONPROFIT VETERAN SERVICE ORGANIZATION IN KANSAS CITY MO. HE IS A FELLOW OF THE AMERICAN ACADEMY OF NEUROLOGY. DR. BIONDI HAS OVER 15 YEARS OF EXPERIENCE IN CLINICAL RESEARCH AND DEVELOPMENT OF PHARMACEUTICALS AND MEDICAL DEVICES IN THE NEUROLOGY, PSYCHIATRY, AND PAIN THERAPEUTIC AREAS. HIS EXPERIENCES INCLUDE THE DESIGN, IMPLEMENTATION, MONITORING, AND INTERPRETATION OF PHASE 2 TO PHASE 4 CLINICAL TRIALS AND IN-HOUSE AND FIELD-BASED ACTIVITIES ASSOCIATED WITH INSIGHTS GENERATION, NEW BUSINESS OPPORTUNITIES, EMERGING HEALTH POLICY, KNOWLEDGE TRANSLATION AND IMPLEMENTATION, AND ORGANIZATIONAL EFFECTIVENESS. HE PREVIOUSLY SERVED AS EXECUTIVE DIRECTOR FOR CLINICAL PROGRAMS WITH COHEN VETERANS BIOSCIENCE. DR. BIONDI RECEIVED HIS MEDICAL DEGREE FROM THE UNIVERSITY OF NEW ENGLAND, COLLEGE OF OSTEOPATHIC MEDICINE IN BIDDEFORD ME. HE COMPLETED RESIDENCY TRAINING IN NEUROLOGY AT THE NATIONAL NAVAL MEDICAL CENTER IN BETHESDA MD AND IS BOARD-CERTIFIED IN NEUROLOGY WITH SUBSPECIALTY EXPERTISE IN HEADACHE AND PAIN MEDICINE. HE RECEIVED HIS BACHELOR OF SCIENCE - MAGNA CUM LAUDE IN PHARMACY FROM THE LONG ISLAND UNIVERSITY, SCHWARTZ COLLEGE OF PHARMACY & HEALTH SCIENCE IN BROOKLYN NY. BOARD MEMBER, DR. DAVE DEMARCO IS A SENIOR ADVISOR TO C-SUITE LEADERS IN THE LIFE SCIENCES AND HEALTHCARE INDUSTRIES. HE SERVES AS CHIEF STRATEGY OFFICER FOR MATERIAL HEALTH STRATEGIES AND WORKS WITH C-SUITE EXECUTIVES ON GROWTH STRATEGIES AND TEAM PERFORMANCE IN BOTH THE FOR-PROFIT AND NOT-FOR-PROFIT INDUSTRIES. HE PREVIOUSLY SERVED AS CHAIR OF THE BOARD OF THE AMERICAN DIABETES ASSOCIATION, LED ERNST & YOUNG'S (EY'S) NORTHEAST LIFE SCIENCES PRACTICE AND WAS THE DEPUTY LEADER OF THE US HEALTHCARE PRACTICE. WITH OVER 25 YEARS OF LEADERSHIP EXPERIENCE, DAVE ADVISES, COACHES AND SHARES INSIGHTS ON STRATEGY AND TRANSFORMATION, COMMERCIAL OPERATIONS, HEALTHCARE POLICY, GOVERNANCE, PUBLIC-PRIVATE-PARTNERSHIPS, AND ENTREPRENEURIAL GROWTH. WHILE SERVING ON THE BOARD OF THE AMERICAN DIABETES ASSOCIATION, HE LED BOARD INITIATIVES INVOLVING: CEO SUCCESSION, PRINCIPAL OFFICER SUCCESSION, BOARD DEVELOPMENT, POLICY CREATION, STRATEGIC PLAN IMPLEMENTATION AND TECHNOLOGY PARTNERSHIPS. DAVE HAS HELD KEY EXECUTIVE POSITIONS, INCLUDING: GLOBAL AESTHETIC FRANCHISE LEADER, SANOFI AVENTIS; US HEALTH DEPUTY LEADER, NORTHEAST REGION LIFE SCIENCES PRACTICE LEADER AND JOHNSON & JOHNSON GLOBAL CLIENT SERVICES PARTNER, EY; RESEARCH SCIENTIST, INTERNAL VENTURE LEADER, AMOCO CHEMICAL; AND COFOUNDER, IDEA CONNECTION SYSTEMS. DAVE WORKED CLOSELY WITH THE AVENTIS NA LEADERSHIP TEAM TO DEVELOP POST-MERGER INTEGRATION GROWTH STRATEGIES AND LAUNCH KEY BLOCKBUSTER PRODUCTS AIMED AT, AND SUCCEEDING IN, DOUBLING THE SIZE OF THE BUSINESS IN FOUR YEARS. AS A SENIOR PARTNER IN EY'S GLOBAL LIFE SCIENCES TEAM, DAVE PILOTED A NEW P&L ACCOUNTABLE, GO-TO-MARKET MODEL, GROWING THE NORTHEAST PRACTICE AT 30% CAGR, RESULTING IN A $400 MILLION BUSINESS. IN HIS SERVICE TO JOHNSON & JOHNSON, HE PARTNERED WITH J&J LEADERSHIP IN DEVELOPING JANSSEN HEALTHCARE INNOVATION, CHARGED WITH CREATING FUTURE BUSINESS UNITS. DAVE LED THE TRANSFORMATION OF EY'S US HEALTH PRACTICE, RESULTING IN A $750 MILLION BUSINESS. AS A MEMBER OF THE SANOFI AVENTIS NA DERMATOLOGY LEADERSHIP TEAM, DAVE DEVELOPED THE GLOBAL AESTHETIC FRANCHISE STRATEGY AND SERVED AS THE COMMERCIAL HEAD FOR EUROPE. FOR THIS TURNAROUND PROJECT, HE CREATED A PLAN TO TRIPLE EBITDA, IMPLEMENT NEW GLOBAL PRICING POLICIES AND DOUBLE CUSTOMER ACQUISITION. DAVE RECEIVED HIS B.S. FROM GROVE CITY COLLEGE AND PH.D. IN CHEMISTRY FROM PURDUE UNIVERSITY.

Return Reference

Explanation

SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:

HRA FORFEITURES - 2020 AMOUNT: $ 28,475. STIMULUS/COVID CREDITS - 2020 AMOUNT: $ 3,629. 2021 AMOUNT: $ 2,480. OTHER REFUNDS - 2021 AMOUNT: $ 110,255. OTHER INCOME - 2022 AMOUNT: $ 37,205. GRANT REFUNDS - 2022 AMOUNT: $ 326,982.

PART II SECT C LINE 17A FACTS & CIRCUMSTANCES TEST (CONT):

DR. HAAS HAS OVER 20 YEARS OF PHARMACEUTICAL EXECUTIVE AND CLINICAL RESEARCH EXPERIENCE INCLUDING DEVELOPMENT LEADERSHIP ROLES IN MEDICAL MARKETING, FULL CLINICAL DEVELOPMENT, EARLY DEVELOPMENT, AND TRANSLATIONAL AND BIOMARKER SCIENCES IN PSYCHIATRY AND NEUROLOGY. DURING HER TENURE AT JOHNSON & JOHNSON, SHE SUCCESSFULLY FILED NDAS IN THE US AND EUROPE FOR RISPERIDONE INDICATIONS IN AUTISM, ADOLESCENT SCHIZOPHRENIA, JUVENILE BIPOLAR DISORDER AND CONDUCT DISORDERS. SHE ALSO LED DEVELOPMENT TEAMS EVALUATING COMPOUNDS FOR DEPRESSION, NEUROPATHIC PAIN, EPILEPSY, AND MIGRAINE DISORDER. SHE SERVED 3 YEARS AS CHIEF SCIENCE AND TECHNOLOGY OFFICER FOR ONE MIND FOR RESEARCH, A NONPROFIT ORGANIZATION LAUNCHED IN MAY 2012 BY PATRICK J KENNEDY. SHE ORCHESTRATED THE LAUNCH OF ONE MIND'S SEMINAL PROGRAMS, APOLLO, AN INFORMATICS RESEARCH PORTAL AND, GEMINI, AN INTERNATIONAL TBI/PTSD RESEARCH PROGRAM. AS AN "INTRAPRENEUR" AT J&J SHE ESTABLISHED THE FIRST NEUROSCIENCE TRANSLATIONAL MEDICINE & INTEGRATIVE SOLUTIONS DEPARTMENT, AND CO-FOUNDED THE FIRST COMPANION DIAGNOSTICS CENTER OF EXCELLENCE AS WELL AS J&J'S HEALTHCARE INNOVATION TEAM. SHE SERVES ON SEVERAL ADVISORY BOARDS INCLUDING ALTO NEUROSCIENCE, KREMBIL CENTRE FOR NEUROINFORMATICS, VIRTUALBRAINCLOUD, PARTNERSHIP FOR ASSESSMENT AND ACCREDITATION OF SCIENTIFIC PRACTICE (PAASP) AND INTERUNIVERSITY MICROELECTRONICS CENTRE (IMEC) AN INTERNATIONAL RESEARCH & DEVELOPMENT AND INNOVATION HUB. DR. HAAS EARNED HER BS IN BIOENGINEERING FROM THE UNIVERSITY OF PENNSYLVANIA, AN MS IN BIOMEDICAL ENGINEERING FROM RUTGERS UNIVERSITY, NEW JERSEY, AND HER MD PHD WITH DISTINCTION IN NEUROSCIENCE FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, NEW YORK. BOARD MEMBER, SECRETARY, THERESA FRANGIOSA HAS EXTENSIVE EXECUTIVE EXPERIENCED BASED ON HER 25 YEAR CAREER WITH THE PHARMACEUTICAL SECTOR. IN HER ROLES WITHIN PHARMA, SHE WAS A GLOBAL LAUNCH LEADER AS WELL AS OVERSEEING EARLY COMMERCIAL STRATEGY IN NEUROSCIENCES. SHE LED LARGE SCALE TEAMS, CROSS-FUNCTIONAL TEAMS TO DEFINE DISEASE AND THERAPEUTIC AREA STRATEGIES FOR JANSSEN AND GLAXOSMITHKLINE. SHE HAS ALSO LED INDICATION PRIORITIZATION EFFORTS AND DEVELOPMENT OF OVER 200 TARGET PRODUCT PROFILES OVER A VARIETY OF DISEASE STATES, LEVERAGING WELL-ESTABLISHED PROCESSES AND FRAMEWORKS, INCLUDING DEEPER UNDERSTANDING OF PATIENT JOURNEYS TO CREATE KEY INSIGHTS. SHE HAS APPLIED HER PROFESSIONAL CAREER EXPERIENCE AND HER PASSION FOR ADVOCACY TO HELP CREATE A CHANNEL FOR FEEDBACK FROM THOSE DIAGNOSED WITH OR AT RISK FOR ALZHEIMER'S DISEASE OR DEMENTIA, THEIR CARE PARTNERS AND INDIVIDUALS WHO ARE 'WORRIED WELL', CALLED THE A-LIST. SHE IS THE LEAD INVESTIGATOR FOR THIS RESEARCH STUDY WITH IRB OVERSIGHT. MS. FRANGIOSA OBTAINED HER BACHELOR OF ADMINISTRATION, ACCOUNTING CONCENTRATION FROM URSINUS COLLEGE (COLLEGEVILLE, PA) IN 1988 AND HER MASTERS OF BUSINESS ADMINISTRATION, PHARMACEUTICAL MARKETING FROM ST. JOSEPH'S UNIVERSITY IN 1996. BOARD MEMBER, TREASURER, MICHAEL C. SULLIVAN IS THE CHIEF OF STAFF AND HEAD OF EXTERNAL AFFAIRS OF POINT72 ASSET MANAGEMENT. MR. SULLIVAN PREVIOUSLY SERVED AS A SENIOR AIDE IN THE UNITED STATES SENATE, FOCUSING ON TELECOM, TECHNOLOGY, AND FINANCE ISSUES. MR. SULLIVAN ALSO SERVED AS A STAFF MEMBER IN THE U.S. HOUSE OF REPRESENTATIVES WORKING ON SIMILAR ISSUES. BEFORE COMING TO CAPITOL HILL, MR. SULLIVAN WAS THE HEAD OF STRATEGIC DEVELOPMENT FOR A TELECOMMUNICATIONS FOCUSED TRADE ASSOCIATION. MR. SULLIVAN IS INVOLVED WITH SEVERAL VETERANS' MENTAL HEALTH-RELATED NONPROFIT ORGANIZATIONS. HE HELPED ESTABLISH AND SERVES ON THE BOARD AND AS TREASURER OF THE COHEN VETERANS NETWORK, WHICH OPERATES A NATIONAL NETWORK OF CLINICS TO TREAT VETERANS AND THEIR FAMILY MEMBERS AFFECTED BY POST-TRAUMATIC STRESS. MR. SULLIVAN IS AN ASSOCIATE AT THE NYU-STERN ENDLESS FRONTIER LABS, WHERE HE MENTORS START-UP COMPANIES IN ARTIFICIAL INTELLIGENCE, MACHINE LEARNING, AND RELATED FIELDS. HE IS ALSO A MEMBER OF THE EXECUTIVE COMMITTEE OF STUDENTS FIRST NEW YORK, A NONPROFIT ORGANIZATION ADVOCATING FOR EDUCATIONAL REFORM IN NEW YORK STATE. MR. SULLIVAN IS A GRADUATE OF VANDERBILT UNIVERSITY. BOARD MEMBER, DAVID BIONDI, MD HAS OVER 20 YEARS OF CLINICAL EXPERIENCE IN MEDICAL PRACTICE AND HELD MEDICAL DIRECTORSHIPS AT THE US NAVAL HOSPITAL IN OKINAWA JAPAN, THE PAIN MANAGEMENT PROGRAM & HEADACHE INSTITUTE AT MARYVIEW MEDICAL CENTER IN PORTSMOUTH VA, THE PAIN DIVISION OF THE MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE IN ANN ARBOR MI, AND THE INTERDISCIPLINARY HEADACHE & PAIN REHABILITATION PROGRAM AT SPAULDING REHABILITATION HOSPITAL IN BOSTON MA. HE WAS PREVIOUSLY AN ASSISTANT NEUROLOGIST AT THE MASSACHUSETTS GENERAL HOSPITAL AND AN INSTRUCTOR IN NEUROLOGY AT HARVARD MEDICAL SCHOOL. DR. BIONDI SERVED AS A TRUSTEE FOR THE UNIVERSITY OF NEW ENGLAND AND WAS CHAIR OF ITS ACADEMIC AND RESEARCH AFFAIRS COMMITTEE AND VICE-CHAIR OF ITS LONG-RANGE PLANNING COMMITTEE. HE ALSO SERVED AS A DIRECTOR AND MEDICAL ADVISOR FOR THE AFTER ACTION NETWORK, A NONPROFIT VETERAN SERVICE ORGANIZATION IN KANSAS CITY MO. HE IS A FELLOW OF THE AMERICAN ACADEMY OF NEUROLOGY. DR. BIONDI HAS OVER 15 YEARS OF EXPERIENCE IN CLINICAL RESEARCH AND DEVELOPMENT OF PHARMACEUTICALS AND MEDICAL DEVICES IN THE NEUROLOGY, PSYCHIATRY, AND PAIN THERAPEUTIC AREAS. HIS EXPERIENCES INCLUDE THE DESIGN, IMPLEMENTATION, MONITORING, AND INTERPRETATION OF PHASE 2 TO PHASE 4 CLINICAL TRIALS AND IN-HOUSE AND FIELD-BASED ACTIVITIES ASSOCIATED WITH INSIGHTS GENERATION, NEW BUSINESS OPPORTUNITIES, EMERGING HEALTH POLICY, KNOWLEDGE TRANSLATION AND IMPLEMENTATION, AND ORGANIZATIONAL EFFECTIVENESS. HE PREVIOUSLY SERVED AS EXECUTIVE DIRECTOR FOR CLINICAL PROGRAMS WITH COHEN VETERANS BIOSCIENCE. DR. BIONDI RECEIVED HIS MEDICAL DEGREE FROM THE UNIVERSITY OF NEW ENGLAND, COLLEGE OF OSTEOPATHIC MEDICINE IN BIDDEFORD ME. HE COMPLETED RESIDENCY TRAINING IN NEUROLOGY AT THE NATIONAL NAVAL MEDICAL CENTER IN BETHESDA MD AND IS BOARD-CERTIFIED IN NEUROLOGY WITH SUBSPECIALTY EXPERTISE IN HEADACHE AND PAIN MEDICINE. HE RECEIVED HIS BACHELOR OF SCIENCE - MAGNA CUM LAUDE IN PHARMACY FROM THE LONG ISLAND UNIVERSITY, SCHWARTZ COLLEGE OF PHARMACY & HEALTH SCIENCE IN BROOKLYN NY. BOARD MEMBER, DR. DAVE DEMARCO IS A SENIOR ADVISOR TO C-SUITE LEADERS IN THE LIFE SCIENCES AND HEALTHCARE INDUSTRIES. HE SERVES AS CHIEF STRATEGY OFFICER FOR MATERIAL HEALTH STRATEGIES AND WORKS WITH C-SUITE EXECUTIVES ON GROWTH STRATEGIES AND TEAM PERFORMANCE IN BOTH THE FOR-PROFIT AND NOT-FOR-PROFIT INDUSTRIES. HE PREVIOUSLY SERVED AS CHAIR OF THE BOARD OF THE AMERICAN DIABETES ASSOCIATION, LED ERNST & YOUNG'S (EY'S) NORTHEAST LIFE SCIENCES PRACTICE AND WAS THE DEPUTY LEADER OF THE US HEALTHCARE PRACTICE. WITH OVER 25 YEARS OF LEADERSHIP EXPERIENCE, DAVE ADVISES, COACHES AND SHARES INSIGHTS ON STRATEGY AND TRANSFORMATION, COMMERCIAL OPERATIONS, HEALTHCARE POLICY, GOVERNANCE, PUBLIC-PRIVATE-PARTNERSHIPS, AND ENTREPRENEURIAL GROWTH. WHILE SERVING ON THE BOARD OF THE AMERICAN DIABETES ASSOCIATION, HE LED BOARD INITIATIVES INVOLVING: CEO SUCCESSION, PRINCIPAL OFFICER SUCCESSION, BOARD DEVELOPMENT, POLICY CREATION, STRATEGIC PLAN IMPLEMENTATION AND TECHNOLOGY PARTNERSHIPS. DAVE HAS HELD KEY EXECUTIVE POSITIONS, INCLUDING: GLOBAL AESTHETIC FRANCHISE LEADER, SANOFI AVENTIS; US HEALTH DEPUTY LEADER, NORTHEAST REGION LIFE SCIENCES PRACTICE LEADER AND JOHNSON & JOHNSON GLOBAL CLIENT SERVICES PARTNER, EY; RESEARCH SCIENTIST, INTERNAL VENTURE LEADER, AMOCO CHEMICAL; AND COFOUNDER, IDEA CONNECTION SYSTEMS. DAVE WORKED CLOSELY WITH THE AVENTIS NA LEADERSHIP TEAM TO DEVELOP POST-MERGER INTEGRATION GROWTH STRATEGIES AND LAUNCH KEY BLOCKBUSTER PRODUCTS AIMED AT, AND SUCCEEDING IN, DOUBLING THE SIZE OF THE BUSINESS IN FOUR YEARS. AS A SENIOR PARTNER IN EY'S GLOBAL LIFE SCIENCES TEAM, DAVE PILOTED A NEW P&L ACCOUNTABLE, GO-TO-MARKET MODEL, GROWING THE NORTHEAST PRACTICE AT 30% CAGR, RESULTING IN A $400 MILLION BUSINESS. IN HIS SERVICE TO JOHNSON & JOHNSON, HE PARTNERED WITH J&J LEADERSHIP IN DEVELOPING JANSSEN HEALTHCARE INNOVATION, CHARGED WITH CREATING FUTURE BUSINESS UNITS. DAVE LED THE TRANSFORMATION OF EY'S US HEALTH PRACTICE, RESULTING IN A $750 MILLION BUSINESS. AS A MEMBER OF THE SANOFI AVENTIS NA DERMATOLOGY LEADERSHIP TEAM, DAVE DEVELOPED THE GLOBAL AESTHETIC FRANCHISE STRATEGY AND SERVED AS THE COMMERCIAL HEAD FOR EUROPE. FOR THIS TURNAROUND PROJECT, HE CREATED A PLAN TO TRIPLE EBITDA, IMPLEMENT NEW GLOBAL PRICING POLICIES AND DOUBLE CUSTOMER ACQUISITION. DAVE RECEIVED HIS B.S. FROM GROVE CITY COLLEGE AND PH.D. IN CHEMISTRY FROM PURDUE UNIVERSITY.

Schedule A (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or other property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990 or 990-EZ), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling $5,000 or more during the year ......... Arrow Bullet

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990) (2022)

Schedule B (Form 990) (2022) Page 2

Name of organization COHEN VETERANS BIOSCIENCE INC

Part I Contributors	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990) (2022)

Schedule B (Form 990) (2022)

Page 3

Name of organization COHEN VETERANS BIOSCIENCE INC		Employer identification number 47-1981973

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990) (2022)

Schedule B (Form 990) (2022)

Page 4


Name of organization COHEN VETERANS BIOSCIENCE INC			Employer identification number 47-1981973
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990) (2022)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

If the organization answered "Yes" on Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" on Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" on Form 990, Part IV, Line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV. See instructions for definition of “political campaign activities."

Political campaign activity expenditures. See instructions .................................................................... SchCMd Bullet

Volunteer hours for political campaign activities. See instructions ..................................................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ................................ SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ....................... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? .........................................

Yes No

Was a correction made? ......................................................................................................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ............................................................................................................................ SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b........... SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ...................................................................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.
1
2
3
4
5
6

For Paperwork Reduction Act Notice, see the instructions for Form 990.

Cat. No. 50084S

Schedule C (Form 990) 2021

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......................	0
b	Total lobbying expenditures to influence a legislative body (direct lobbying) ........................	120,000
c	Total lobbying expenditures (add lines 1a and 1b) ............................................................	120,000
d	Other exempt purpose expenditures ...............................................................................	15,221,366
e	Total exempt purpose expenditures (add lines 1c and 1d) ..................................................	15,341,366
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	917,068
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................................................	229,267
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................................................	0
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................................................	0
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ...................................................................................................................		Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) Total

2a	Lobbying nontaxable amount	1,000,000	1,000,000	1,000,000	917,068	3,917,068

b	Lobbying ceiling amount (150% of line 2a, column(e))					5,875,602

c	Total lobbying expenditures	90,000	90,000	90,000	120,000	390,000

d	Grassroots nontaxable amount	250,000	250,000	250,000	229,267	979,267

e	Grassroots ceiling amount (150% of line 2d, column (e))					1,468,901

f	Grassroots lobbying expenditures

Schedule C (Form 990) 2021

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes|No

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? ...........................................................................................................

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ........

Media advertisements? ...................................................................................................

Mailings to members, legislators, or the public? .............................................................................

Publications, or published or broadcast statements? ...........................................................

Grants to other organizations for lobbying purposes? ..........................................................

Direct contact with legislators, their staffs, government officials, or a legislative body? .......................

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ..................

Other activities? ...................................................................................................................

Total. Add lines 1c through 1i ....................................................................................................

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 ...........................................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 ...................

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? ........................

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ...............................................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ............................................

Did the organization agree to carry over lobbying and political expenditures from the prior year? .................................

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members ......................................................................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).

Current year .............................................................................................................................

Carryover from last year ............................................................................................................

Total ...........................................................................................................................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ......................................................................................................................

Taxable amount of lobbying and political expenditures. See Instructions .........................................

Part IV

Supplemental Information

Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions), and Part ll-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation

Schedule C (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet

Attach to Form 990.
SchDMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... SchDMd Bullet

(ii)

Assets included in Form 990, Part X ............................... SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2021

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....
b	Contributions ...
c	Net investment earnings, gains, and losses
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...
f	Administrative expenses ....
g	End of year balance ......

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

Permanent endowment SchDMd Bullet

Term endowment SchDMd Bullet

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .................

3a(i)

(ii) Related organizations .................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....
b	Buildings ....
c	Leasehold improvements	134,362	68,836	65,526
d	Equipment ....	174,076	99,079	74,997
e	Other .....	2,200,046	373,112	1,826,934
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				1,967,457

Schedule D (Form 990) 2021

Page 3

Part VII

Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value
(1)DEPOSITS				30,968
(2)OPERATING LEASE RIGHT-OF-USE ASSET				1,168,240
(3)DEPOSITS AND OTHER ASSETS				415,451
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........				1,614,659

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	1,294,809
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) 2021

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......		1	11,343,534
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a
b	Donated services and use of facilities .........	2b
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................		2e	0
3	Subtract line 2e from line 1..................		3	11,343,534
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b....................		4c	0
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......		5	11,343,534

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........		1	15,341,366
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d....................		2e	0
3	Subtract line 2e from line 1...................		3	15,341,366
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.....................		4c	0
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......		5	15,341,366

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference

Explanation

PART X, LINE 2:

TAX POSITION: THE ORGANIZATION CURRENTLY EVALUATES ALL TAX POSITIONS AND MAKES A DETERMINATION REGARDING THE LIKELIHOOD OF THOSE POSITIONS BEING UPHELD UNDER REVIEW. THE PRIMARY TAX POSITION MADE BY THE ORGANIZATION IS THE EXISTENCE OF UNRELATED BUSINESS INCOME TAX AND THE ORGANIZATION'S STATUS AS A TAX-EXEMPT PUBLIC CHARITY UNDER IRC SECTION 501(C)(3). FOR THE YEAR PRESENTED, THE ORGANIZATION HAS NOT RECOGNIZED ANY TAX BENEFITS OR LOSS CONTINGENCIES FOR UNCERTAIN TAX POSITIONS BASED ON THIS EVALUATION.

Schedule D (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization
COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
	EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	0	0	GRANTS TO RECIPIENTS LOCATED IN REGION	N/A	90,026
















3a	Sub-total ....	0	0			90,026
b	Total from continuation sheets to Part I ...	0	0			0
c	Totals (add lines 3a and 3b)	0	0			90,026

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2022

Schedule F (Form 990) 2022

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	PLATFORM FOR THE EXCHANGE OF EXPERIMENTAL RESEARCH STANDARDS (PEERS)	55,776	WIRE TRANSFER	0	N/A	N/A
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	PLATFORM FOR THE EXCHANGE OF EXPERIMENTAL RESEARCH STANDARDS (PEERS)	34,250	WIRE TRANSFER	0	N/A	N/A

2	Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......	0
3	Enter total number of other organizations or entities .......................	2

Schedule F (Form 990) 2022

Schedule F (Form 990) 2022Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2022

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2022

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

ReturnReference	Explanation
PART I, LINE 2:	THE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING.
PART III ACCOUNTING METHOD:

Schedule F (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990.
lBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization
COHEN VETERANS BIOSCIENCE INC

Employer identification number
47-1981973

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ........................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient

that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
(1) UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE 0940 LA JOLLA,CA920939040	95-6006144	501(C)3	108,171	0	N/A	N/A	ALCOHOL-PTSD COMORBIDITY: PRECLINICAL STUDIES

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................. Bullet Image

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2022

Page 2

Part III

Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

(1)
(2)
(3)
(4)
(5)
(6)
(7)

Part IV

Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

Return Reference	Explanation
PART I, LINE 2:	THE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING.

Schedule I (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990.
SchJMediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2022

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2, 1099-MISC compensation, and/or 1099-NEC			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1MAGALI HAAS MD PHD CEO & PRESIDENT	(i) (ii)	473,560 ------------- 0	73,875 ------------- 0	0 ------------- 0	18,300 ------------- 0	0 ------------- 0	565,735 ------------- 0	0 ------------- 0
2ALLYSON GAGE PHD CHIEF MEDICAL OFFICER	(i) (ii)	384,589 ------------- 0	97,147 ------------- 0	0 ------------- 0	14,330 ------------- 0	8,305 ------------- 0	504,371 ------------- 0	0 ------------- 0
3AMANDA NICOLE HARMON CHIEF OPERATIONS OFFICER	(i) (ii)	283,405 ------------- 0	81,312 ------------- 0	0 ------------- 0	13,008 ------------- 0	23,441 ------------- 0	401,166 ------------- 0	0 ------------- 0
4LEE LANCASHIRE CHIEF INFORMATION OFFICER	(i) (ii)	310,941 ------------- 0	0 ------------- 0	0 ------------- 0	12,438 ------------- 0	44,929 ------------- 0	368,308 ------------- 0	0 ------------- 0
5EVGENY RAKHMATULIN CHIEF TECHNOLOGY OFFICER	(i) (ii)	241,822 ------------- 0	63,750 ------------- 0	0 ------------- 0	15,504 ------------- 0	23,440 ------------- 0	344,516 ------------- 0	0 ------------- 0
6MARYAN ZIRKLE EXECUTIVE DIRECTOR, BRAINC	(i) (ii)	238,362 ------------- 0	43,326 ------------- 0	0 ------------- 0	17,032 ------------- 0	8,305 ------------- 0	307,025 ------------- 0	0 ------------- 0
7MARK ZERVAS DEPUTY DIRECTOR, TRANSLATI	(i) (ii)	188,176 ------------- 0	29,070 ------------- 0	0 ------------- 0	12,661 ------------- 0	23,440 ------------- 0	253,347 ------------- 0	0 ------------- 0
8LAUREN GOLDSMITH SENIOR DIRECTOR, CONTRACTS	(i) (ii)	227,944 ------------- 0	2,000 ------------- 0	0 ------------- 0	12,722 ------------- 0	9,888 ------------- 0	252,554 ------------- 0	0 ------------- 0
9RENEE DAVIS EXECUTIVE DIRECTOR, DEVELO	(i) (ii)	208,434 ------------- 0	0 ------------- 0	0 ------------- 0	12,001 ------------- 0	6,343 ------------- 0	226,778 ------------- 0	0 ------------- 0
10PETER HOEHN EXECUTIVE VP, MARKING STRATEGY, DEVE	(i) (ii)	141,346 ------------- 0	42,404 ------------- 0	0 ------------- 0	0 ------------- 0	0 ------------- 0	183,750 ------------- 0	0 ------------- 0
11ANDREW THOMPSON ASSOCIATE DIRECTOR, DATA SCIENCE	(i) (ii)	159,579 ------------- 0	0 ------------- 0	0 ------------- 0	9,700 ------------- 0	8,305 ------------- 0	177,584 ------------- 0	0 ------------- 0

Schedule J (Form 990) 2022

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation

Schedule J (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Return Reference	Explanation
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 WAS REVIEWED BY THE ORGANIZATION'S OUTSOURCED CFO AND THEN REVIEWED, AUTHORIZED AND SIGNED BY THE ORGANIZATION'S CEO & PRESIDENT.
FORM 990, PART VI, SECTION B, LINE 12C	THE BOARD OF DIRECTORS REQUIRES AN ANNUAL DECLARATION FROM ALL BOARD MEMBERS AND SENIOR MANAGEMENT AS TO THE EXISTENCE AND DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTEREST. THE BOARD MEMBERS SIGN A DISCLOSURE STATEMENT. ANY POTENTIAL CONFLICTS ARE DISCUSSED BY THE DIS-INTERESTED BOARD MEMBERS, WHILE THE PARTY IN POTENTIAL CONFLICT IS REQUIRED TO LEAVE THE ROOM. BOARD MEETING MINUTES WILL DOCUMENT THE DISCUSSION AND DECISION MAKING PROCESS. IN THE EVENT OF A POTENTIAL CONFLICT, PROCEDURES TO OBTAIN COMPETITIVE BIDS AND DILIGENCE ON FAIR MARKET VALUE WILL BE ESTABLISHED.
FORM 990, PART VI, SECTION B, LINE 15	CVB'S EXECUTIVE COMPENSATION PROGRAM IS ADMINISTERED BY THE BOARD OF DIRECTORS. THE BOARD IS RESPONSIBLE FOR ESTABLISHING AND MAINTAINING A COMPETITIVE COMPENSATION PROGRAM FOR THE KEY EXECUTIVES OF THE ORGANIZATION. THE BOARD MEETS AS NEEDED TO REVIEW THE COMPENSATION PROGRAM AND MAKE RECOMMENDATIONS FOR ANY CHANGES, AS APPROPRIATE. A PERFORMANCE EVALUATION IS CONDUCTED AND REVIEWED EACH YEAR AND IS INTENDED TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. FOLLOWING THIS REVIEW, THE BOARD REVIEWS AND APPROVES, FOR SELECTED KEY EXECUTIVES, BASE SALARIES AND ANNUAL INCENTIVE OPPORTUNITY ADJUSTMENTS, AND OBJECTIVES AND GOALS UPCOMING YEAR'S ANNUAL INCENTIVE PLAN. THE BOARD REVIEWS AND RECOMMENDS TO THE BOARD SALARY APPROVAL AND INCENTIVE AWARDS FOR THE CEO/PRESIDENT AND SELECTED KEY SENIOR STAFF.
FORM 990, PART VI, SECTION C, LINE 19	UPON REQUEST AND FORMS AVAILABLE THROUGH CHARITY NAVIGATOR WEBSITE AS WELL.
FORM 990, PART IX, LINE 11G	OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 183,849. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 183,849. RESEARCH COLLABORATION EXPENSES: PROGRAM SERVICE EXPENSES 597,783. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 597,783. CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 3,986,265. MANAGEMENT AND GENERAL EXPENSES 38,285. FUNDRAISING EXPENSES 21,188. TOTAL EXPENSES 4,045,738.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

COHEN VETERANS BIOSCIENCE INC

Employer identification number

47-1981973

Part I

Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
(1) EARLY SIGNAL LLC 251 LITTLE FALLS DRIVE WILMINGTON,DE19808	TO HOLD INTELLECTUAL PROPERTY	DE	0	0	COHEN VETERANS BIOSCIENCE INC
(2) BRAINCOMMONS LLC 251 LITTLE FALLS DRIVE WILMINGTON,DE19808	TO HOLD INTELLECTUAL PROPERTY	DE	0	0	COHEN VETERANS BIOSCIENCE INC

Part II

Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2021

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	Yes	No

Schedule R (Form 990) 2021

Page 3

Part V

Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity .....................

b Gift, grant, or capital contribution to related organization(s) ............................

c Gift, grant, or capital contribution from related organization(s) ............................

d Loans or loan guarantees to or for related organization(s) ............................

e Loans or loan guarantees by related organization(s) ............................

f Dividends from related organization(s) ............................

g Sale of assets to related organization(s) ............................

h Purchase of assets from related organization(s) ............................

i Exchange of assets with related organization(s) ............................

j Lease of facilities, equipment, or other assets to related organization(s) .......................

k Lease of facilities, equipment, or other assets from related organization(s) ......................

l Performance of services or membership or fundraising solicitations for related organization(s) .....................

m Performance of services or membership or fundraising solicitations by related organization(s) .................

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) ...................

o Sharing of paid employees with related organization(s) ............................

p Reimbursement paid to related organization(s) for expenses ............................

q Reimbursement paid by related organization(s) for expenses ............................

r Other transfer of cash or property to related organization(s) ............................

s Other transfer of cash or property from related organization(s) ............................

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved

Schedule R (Form 990) 2021

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Schedule R (Form 990) 2021

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.

Return Reference	Explanation

Schedule R (Form 990) 2021

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	5
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	4
5	Total number of individuals employed in calendar year 2021 (Part V, line 2a) ......	5	36
6	Total number of volunteers (estimate if necessary) .............	6	50
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, Part I, line 11 .........	7b	0

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	17,941,055	10,755,381
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	28,608	223,966
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	112,735	364,187
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	18,082,398	11,343,534
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	501,347	198,197
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	7,547,333	6,759,744
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	36,000	0
b	Total fundraising expenses (Part IX, column (D), line 25) 430,116
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	9,439,104	8,383,425
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	17,523,784	15,341,366
19	Revenue less expenses. Subtract line 18 from line 12.......	558,614	-3,997,832
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	15,587,351	11,743,398
21	Total liabilities (Part X, line 26).............	3,699,826	3,853,705
22	Net assets or fund balances. Subtract line 21 from line 20.....	11,887,525	7,889,693

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 13,585,394 including grants of $ 198,197 ) (Revenue $ 0 )
	BRAIN HEALTH TOOLS & TECHNOLOGIES:IN ORDER TO FAST-TRACK PRECISION DIAGNOSTICS AND TARGETED THERAPEUTICS AND WELLNESS APPROACHES FOR MAINTENANCE AND RESTORATION OF BRAIN HEALTH, CVB IS LEVERAGING INNOVATION AND TECHNOLOGY TO BUILD TOOLS AND PLATFORMS THAT ENABLE DISCOVERY AND DEVELOPMENT ACROSS BRAIN DISEASES. THESE TOOLS & PLATFORMS ALLOW RESEARCHERS FROM ACADEMIA AND INDUSTRY TO ACCESS AND UTILIZE BEST-IN-CLASS PRACTICES AND ALLOW EFFORTS TO BE SCALED WITH RIGOR AND REPRODUCIBILITY.(SEE SCHEDULE O FOR FULL DETAIL OF OUR PROGRAMS)PLATFORM EFFORTS FOCUS ON CAPACITY THAT ENABLES RELIABLE DISCOVERY OF BIOMARKERS AND BIOLOGICAL PATHWAYS THAT ARE TRANSLATIONALLY RELEVANT FOR THE DEVELOPMENT OF DIAGNOSTICS AND THERAPEUTIC TARGETS FOR DRUG AND OTHER MEDICAL INTERVENTIONS. EACH PLATFORM IS CREATING RESEARCH TOOLS (E.G. ANIMAL MODELS, DATA STANDARDS, COMPUTATIONAL MODELS, REFERENCE DATABASES, ETC.) THAT WILL ACCELERATE/FOSTER THESE DISCOVERIES.WITHIN THIS FRAMEWORK, CVB HAS ESTABLISHED BOTH INTRAMURAL (RESEARCH CONDUCTED BY, OR INCLUDING, CVB STAFF OR CONTRACTORS) AND EXTRAMURAL RESEARCH PROGRAMS (RESEARCH CONDUCTED VIA GRANTS OR IN COLLABORATION WITH EXTERNAL ACADEMIC, INDUSTRY, FOUNDATION AND GOVERNMENT PARTNERS) AND ALSO OPERATES SEVERAL PUBLIC-PRIVATE PARTNERSHIPS. THESE COOPERATIVE ALLIANCES ORGANIZE AND FUND A NETWORK OF PARTNERS WHO EACH CONTRIBUTE COMPLEMENTARY AND SYNERGISTIC DATA, CAPABILITIES, OR EXPERTISE TO SUPPORT A COMMON ROADMAP FOR IDENTIFYING DIAGNOSTIC BIOMARKERS, BUILDING PREDICTIVE BRAIN DISEASE MODELS, DEVELOPING ROBUST STANDARDIZED TRANSLATIONAL TOOLS, AND CATALYZING PHARMACEUTICAL DRUG DEVELOPMENT. THE EMPHASIS IS ON TEAM SCIENCE WITH COHEN VETERANS BIOSCIENCE SERVING AS ITS HUB.OUR PLATFORM PROGRAMS CURRENTLY INCLUDE THE BRAINCOMMONS (CLOUD-BASED DATA & ANALYTICS), EARLYSIGNAL (WEARABLE AND HOME SENSORS FOR MONITORING HEALTH STATUS), RAPID-DX (ESTABLISHING BEST PRACTICES FOR DISCOVERY AND VALIDATION OF BIOMARKERS), AMP-IT-UP (FOR PRECLINICAL DISCOVERY AND TRANSLATION) AND TAP (TARGET ADVANCEMENT PROGRAM).BRAINCOMMONS:THE BRAINCOMMONS (BC) IS A CLOUD-BASED RESEARCH AND DISCOVERY PLATFORM FOR THE BRAIN HEALTH COMMUNITY WHICH FEATURES DATA, TOOLS, AND COMMUNITY ACCESS IN A SECURE, SCALABLE, AND SUSTAINABLE ENVIRONMENT. IT IS DESIGNED TO FURTHER DEMOCRATIZE DATA AND ENABLE GREATER COLLABORATION GLOBALLY AMONG BRAIN SCIENTISTS WORKING IN A VARIETY OF SETTINGS.WE ARE IN A NEW ERA OF BRAIN RESEARCH, WHERE POWERFUL DATA ACQUISITION TECHNOLOGIES ARE GENERATING MULTIMODAL DATA AT INCREASING SCALES. TO ENABLE DISEASE MODELING EFFORTS, AS WELL AS THE DISCOVERY AND REPLICATION OF BIOMARKERS, THERE IS A CRITICAL NEED FOR A PLATFORM THAT CAN HOUSE MULTI-MODAL DATA TYPES, ACROSS DIAGNOSTIC CATEGORIES, IN CONJUNCTION WITH DATA PIPELINES TO ENSURE REPRODUCIBLE ANALYSIS, AND WITH AN ABILITY TO APPLY STATE-OF-THE ART MACHINE-LEARNING ALGORITHMS. IN 2022, THE BRAINCOMMONS WAS LAUNCHED TO OUR FIRST COMMUNITY OF RESEARCH PARTNERS IN PTSD, TBI AND PARKINSON'S.IN 2023, WE HAVE LAUNCHED A NEW USER INTERFACE FOR THE BRAINCOMMONS AND HAVE UPLOADED OUR NATIONAL NORMATIVE NEUROIMAGING LIBRARY DATA TO THE PLATFORM TO BE SHARED WITH THE RESEARCH COMMUNITY WITH ACCOMPANYING PIPELINES FOR DATA PROCESSING.EARLYSIGNAL:THE AIM OF OUR DIGITAL HEALTH PROGRAM, EARLY SIGNAL, IS TO RECORD AND ANALYZE A RANGE OF DATA DIRECTLY RELATED TO THE WELL-BEING OF PATIENTS LIVING WITH BRAIN DISORDERS. BEHAVIORAL, COGNITIVE, PHYSIOLOGICAL AND OTHER INFORMATION ARE COLLECTED THROUGH OUR INTEGRATED TECHNOLOGY PLATFORM.WEARABLE AND SENSOR TECHNOLOGIES HOLD PROMISE IN THE ASSESSMENT AND CONTINUOUS MONITORING OF PATIENTS IN ORDER TO BETTER SCREEN AND DIAGNOSE, MONITOR DISEASE PROGRESSION, AND OBSERVE INTERVENTION RESPONSE OR LACK THEREOF. DIGITAL HEALTH MONITORING ALSO ALLOWS US TO STUDY BRAIN HEALTH AND DISEASE IN UNPRECEDENTED WAYS, BY TRACKING VARIABLES SUCH AS SLEEP, PHYSICAL ACTIVITY, STRESS AND COGNITION, WE MAY BE ABLE TO BETTER UNDERSTAND WHAT CHANGES OVER TIME - AND TO DEVELOP EARLIER AND PREVENTIVE DIAGNOSTICS AND TREATMENTS TO MAKE A DIFFERENCE IN PATIENTS' LIVES. MEDICAL-GRADE DATA IS NEEDED FOR FDA APPROVAL OF SUCH PLATFORMS FOR USE IN MEDICAL DECISION MAKING AND DATA INTEGRATION IS NECESSARY FOR CLINICIANS' WORKFLOW. THIS PROGRAM SUPPORTS MULTIPLE PARTNERS TO TEST AND VALIDATE WEARABLES, SENSORS, APPS AND OTHER DIGITAL HEALTH TECHNOLOGIES FOR USE IN MONITORING BRAIN HEALTH. IN 2022, CVB, IN PARTNERSHIP WITH UNIVERSITY OF PENNSYLVANIA, COMPLETED A STUDY TO TEST AND VALIDATE THE PERFORMANCE OF WEARABLE AND SENSOR DEVICES FOR THE ASSESSMENT OF SLEEP COMPARED TO GOLD STANDARD POLY-SOMNOGRAPHY, USING CVB-DESIGNED SECURE AUTOMATED DEIDENTIFIED DATA COLLECTION AND CVB'S STUDY MANAGER TOOL TO SUPPORT CONDUCT OF THE TRIAL. IN 2022, WE COMPLETED THE DEVELOPMENT OF OUR "TRIAL-IN-A-BOX" FULLY AUTOMATED CLINICAL TRIAL SOLUTION FOR THE COLLECTION AND AUTOMATED PROCESSING AND ANALYSIS OF DIGITAL HEALTH DATA IN TRADITIONAL, HYBRID, AND FULLY DECENTRALIZED TRIAL FORMATS. IN THE FULLY DECENTRALIZED SETTING, THIS ALLOWS STUDY SPONSORS TO SEND WEARABLE AND HOME SENSOR TECHNOLOGY STUDY KITS DIRECTLY TO ELIGIBLE STUDY PARTICIPANTS WITHOUT REQUIRING THEM TO VISIT A STUDY CENTER, ENABLING A MORE DIVERSE AND OFTEN LESS-STUDIED POPULATION TO PARTICIPATE. THE PROVIDED DEVICES ARE PAIRED WITH A DOWNLOADABLE STUDY APP ON THE PARTICIPANT'S OWN DEVICE TO COLLECT RELATED SUBJECTIVE OUTCOMES SUCH AS TRADITIONAL SCALES OF DEPRESSION, FUNCTION, AND ACTIVITY AS WELL ECOLOGICAL MOMENTARY ASSESSMENTS.IN 2023, WE LAUNCHED AND COMPLETED THE 40 WINKS SLEEP STUDY A CUTTING-EDGE, VOLUNTARY WEARABLES RESEARCH STUDY AIMING TO IMPROVE AND SIMPLIFY HOW WE MEASURE SLEEP. THE GOAL OF THE 40 WINKS STUDY IS TO EVALUATE AND IMPROVE METHODS OF MEASURING SLEEP AT HOME, WHICH MAY HELP INFORM THE DEVELOPMENT OF DIAGNOSTICS AND TREATMENTS THAT ARE USER-FRIENDLY, COST-EFFECTIVE, AND RELIABLE. THE STUDY RECRUITED HEALTHY ADULT VOLUNTEERS, OR ADULTS SELF-REPORTING INSOMNIA, INCLUDING VETERANS IN BOTH GROUPS.RAPID-DX: RESEARCH ALLIANCE FOR PRECISION THERAPEUTICS, INNOVATION AND DIAGNOSTICS RAPID-DX IS CVB'S FLAGSHIP BIOMARKER DISCOVERY COLLABORATIVE - FAST-TRACKING THE ADVANCEMENT OF OBJECTIVE DIAGNOSTICS FOR BRAIN DISEASES.A BIOMARKER IS A CHARACTERISTIC THAT IS OBJECTIVELY MEASURED AND EVALUATED AS AN INDICATOR OF A NORMAL OR PATHOLOGIC BIOLOGICAL PROCESS OR A RESPONSE TO A THERAPEUTIC INTERVENTION. DEVELOPING BIOMARKER-BASED DIAGNOSTICS IS ESSENTIAL TO SHIFTING DIAGNOSIS AND TREATMENT OF PSYCHIATRIC AND NEUROLOGIC CONDITIONS (SUCH AS PTSD AND TBI) FROM A SYMPTOM-BASED APPROACH TO A BIOLOGICAL, MECHANISTICALLY-BASED ONE THAT TARGETS THE EFFECTS OF TRAUMA AT THEIR MOLECULAR ROOTS. MANY POTENTIAL BRAIN-RELATED BIOMARKERS PUBLISHED IN THE LITERATURE HAVE NOT BEEN INDEPENDENTLY REPLICATED OR ADVANCED THROUGH A QUALIFICATION PROCESS FOR REGULATORY APPROVAL AND USE.RAPID-DX IS A PUBLIC-PRIVATE PARTNERSHIP PROGRAM INCLUDING GOVERNMENT, FOUNDATIONS, AND LEADING ACADEMIC CENTERS ESTABLISHED FOR COLLECTING DATA AND PERFORMING STUDIES NECESSARY TO DISCOVER AND REPLICATE BIOMARKERS AND QUALIFY SUCCESSFUL AND RELEVANT CANDIDATES FOR DEVELOPMENT AS CLINICAL DIAGNOSTICS.THROUGH THIS PROGRAM CVB HAS ESTABLISHED THE CVB BIOREPOSITORY IN PARTNERSHIP WITH INDIANA UNIVERSITY. THE GOAL OF THE BIOREPOSITORY IS TO ESTABLISH A CENTRALIZED RESOURCE FOR TISSUE AND BIOSAMPLE STORAGE FOR ENABLING BIOMARKER DISCOVERY, REPLICATION, AND VALIDATION ACROSS A NUMBER OF BRAIN CONDITIONS, INCLUDING POST-TRAUMATIC STRESS DISORDER ("PTSD"), TRAUMATIC BRAIN INJURY ("TBI"), SUICIDE, DEMENTIA, MAJOR DEPRESSIVE DISORDER AND OTHER MENTAL HEALTH DISORDERS, AMONG OTHERS.THE CVB BRAIN BIOREPOSITORY HOUSES BLOOD AND SALIVA SAMPLES THAT WERE COLLECTED AS PART OF BIOMARKER STUDIES DIRECTLY SPONSORED BY COHEN VETERANS BIOSCIENCE OR THROUGH KEY PARTNERSHIP PROGRAMS. OUR BIOREPOSITORY BANKS A VARIETY OF BIOLOGIC SAMPLES INCLUDING, PLASMA, SERUM, AND SALIVA, AND WILL ENCOURAGE FUTURE COLLABORATIONS WITH RESEARCHERS FROM ACADEMIA, INDUSTRY, GOVERNMENT, AND FOUNDATIONS.BRAIN TRAUMA PROGRAMS: POST TRAUMATIC STRESS DISORDER AND TRAUMATIC BRAIN INJURY. THIS CVB PROGRAM WAS FOUNDED IN 2015 TO ESTABLISH A NATIONAL RESEARCH ROADMAP FOR PTSD, TBI AND RELATED CONDITIONS (E.G. SUICIDALITY). BRAIN TRAUMA BLUEPRINT - STATE OF THE SCIENCE SUMMITS:THE BRAIN TRAUMA BLUEPRINT (HTTPS://WWW.BRAINTRAUMABLUEPRINT.ORG/) IS A FRAMEWORK TO ESTABLISH ROADMAPS TO ADVANCE PRECISION DIAGNOSTICS AND THERAPEUTICS FOR SURVIVORS OF BRAIN TRAUMA BY OUTLINING RESEARCH GOALS & PRIORITIES, ESTABLISHING CONSENSUS AROUND FAILURE MODES & KNOWLEDGE GAPS, AND DEVELOPING STRATEGIES TO MOVE THE FIELD FORWARD FOR TRAUMA-RELATED CONDITIONS BY FOSTERING COLLABORATION AND RESOURCE ALLOCATION ACROSS THE BROADER STAKEHOLDER COMMUNITY.

4b	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )
	THE STATE OF THE SCIENCE SUMMITS ARE THE BASIS FOR BUILDING THE ROADMAPS AND ARE DESIGNED AS RETREATS FOR 100 TO 200 STAKEHOLDERS TO COME TOGETHER TO REALIZE TRUE IMPACT. THE STAKEHOLDERS ENCOMPASS A BROAD SWATH OF THE COMMUNITY FROM ACADEMIC INSTITUTIONS TO GOVERNMENT AGENCIES, FOUNDATIONS SUPPORTING TRANSLATIONAL RESEARCH, INDUSTRY AND INDIVIDUALS WITH LIVED EXPERIENCE.EACH SUMMIT SERVES AS A LAUNCHPAD FOR ONGOING WORKING GROUPS TO DEVELOP EVIDENCE-BASED STRATEGIES AND RECOMMENDATIONS ON HOW TO FILL THOSE GAPS, IDENTIFY NEW GAPS AS OTHERS ARE FILLED, AND DISSEMINATE THESE FINDINGS BACK TO THE COMMUNITY AT LARGE THROUGH WHITE PAPERS AND PROCEEDINGS.THE INAUGURAL STATE OF THE SCIENCE SUMMIT ("SOSS"), HELD IN 2018, FOCUSED ON DIAGNOSIS OF TRAUMA-RELATED BRAIN DISORDERS WITH A MAJOR FOCUS ON POST-TRAUMATIC STRESS DISORDER. THE TRAUMA-RELATED BRAIN DISORDERS RESEARCH COMMUNITY HAS IDENTIFIED A NEED TO ESTABLISH A MECHANISM-BASED TAXONOMY FOR THESE CONDITIONS TO ADVANCE BIOMARKER DISCOVERY AS WELL AS DIAGNOSIS AND THERAPEUTIC DEVELOPMENT. A SHIFT FROM A SYNDROMIC CLASSIFICATION SYSTEM TO A MECHANISTIC ONE NECESSITATES A REVIEW OF THE CURRENT SCIENTIFIC KNOWLEDGE, ADOPTION OF NEW SCIENTIFIC MODELS, AND IDENTIFICATION OF RESEARCH AND KNOWLEDGE GAPS. THE SOSS BROUGHT TOGETHER MULTIDISCIPLINARY STAKEHOLDERS WITH DEEP SCIENTIFIC AND CLINICAL EXPERTISE TO ADDRESS THIS PRESSING NEED.THE THEME OF THE SECOND STATE OF THE SCIENCE SUMMIT, HELD IN 2019 WAS PATHS TO TREATMENT FOR TRAUMATIC BRAIN INJURY(S) WITH A FOCUS ON THE TAXONOMY AND NOSOLOGY OF THE CHRONIC SEQUELAE, CHALLENGES AND OPPORTUNITIES IN CLINICAL PRACTICE AND DEVELOPMENT, AND ETIOLOGY AND MECHANISM OF PERSISTENT SYMPTOMS. AS MEASUREMENT TOOLS ADVANCE, RESEARCH HAS BEEN ABLE TO FOCUS ON DIFFERENT TYPES OF INJURY, BEYOND THE MILD, MODERATE, AND SEVERE CLASSIFICATIONS OF TBI. TO AUGMENT AND SUPPORT THE MANY EFFORTS ACROSS FIELDS AND ORGANIZATIONS OVER THE PAST DECADE, IN 2020 WE WORKED WITH THOUGHT LEADERS ACROSS TBI TO PREPARE A CONSENSUS BLUEPRINT TO DRIVE TRANSLATIONAL SCIENCE FOR TBI. IN 2021, WE PUBLISHED RECOMMENDATIONS IN SUPPORT OF THE NATIONAL TBI PRECISION RESEARCH ROADMAP.IN 2022, WE LAUNCHED THE TBI ACTION ALLIANCE IN SUPPORT OF A NATIONAL TBI PRECISION RESEARCH ROADMAP. THE ROADMAP, BASED ON RECOMMENDATIONS FROM THE BRAIN TRAUMA EXPERT COMMUNITY, OUTLINES A SERIES OF CRITICAL PROJECTS WITH SPECIFIED MILESTONES THAT WILL MATERIALLY ADVANCE PROGRESS TOWARDS THE STATED GOALS OF "ADVANCING A FIRST GENERATION OF TBI DIAGNOSTICS AND TREATMENTS".THE TBI PRECISION RESEARCH ROADMAP FOCUSES ON 7 LINES OF EFFORT:1. INJURY BURDEN: IDENTIFY THE BURDEN OF DISEASE ACROSS ALL POPULATIONS AND INJURY SEVERITIES AS DETERMINED BY INCIDENCE, PREVALENCE AND LONG-TERM TRAJECTORIES OF PATIENTS SUFFERING FROM TBI.2. DISEASE MODELS: DEVELOP AN ARRAY OF TRANSLATIONALLY VALID DISEASE MODELS (PRECLINICAL AND COMPUTATIONAL) BASED ON BIOLOGICAL UNDERSTANDING OF TRAUMA PATHOGENESIS AND DISEASE PHENOTYPES THAT SUPPORT EVALUATION OF NOVEL THERAPIES.3. PRECISION DIAGNOSIS: IDENTIFY, DEVELOP AND VALIDATE DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE BIOMARKERS FORTBI TO DEVELOP FIRST GENERATION DIAGNOSTIC TESTS.4. TARGETED THERAPEUTICS: VALIDATE THERAPEUTIC TARGETS & FAST TRACK A FIRST-GENERATION OF TBI (WELLNESS, DEVICE, DIGITAL, DRUG) THERAPEUTICS TARGETED TO THE RIGHT PERSON AT THE RIGHT TIME.5. CLINICAL PRACTICE IMPLEMENTATION: ACCELERATE ADOPTION OF BEST PRACTICES, CLINICAL PRACTICE GUIDELINES, AND PRECISION THERAPEUTIC APPROACHES TO OPTIMIZE BRAIN HEALTH OUTCOMES.6. TRANSLATIONAL INFRASTRUCTURE AND ENABLINGTECHNOLOGIES: IDENTIFY AND ADDRESS INFRASTRUCTURE,INCENTIVES, REGULATORY AND TECHNOLOGY GAPS TO ADVANCE THE TBI ROADMAP.7. AWARENESS AND ADVOCACY: PLACE TBI AT THE TOP OF THE U.S. PUBLIC POLICY AGENDA AND RAISE AWARENESS TO REDUCE STIGMA OF BRAIN INJURY, ENCOURAGE TREATMENT-SEEKING, AND ENABLE ACCESS AND REIMBURSEMENT OF CARE.IN 2023 WE LAUNCHED THE TBI ACTION ALLIANCE TO SUPPORT THE EXECUTION OF THE NATIONAL TBI ROADMAP THROUGH A PUBLIC-PRIVATE PARTNERSHIP MODEL THAT ENGAGES MULTIPLE SECTORS TO ADVANCE THE OBJECTIVES OUTLINED IN THE ROADMAP. (TBIACTION.ORG)RAPID-DIAGNOSTICS (RAPID-DX) - RESEARCH STUDIES:BEST BIOMARKER PTSD STUDY:DESPITE THE EFFICACY OF PSYCHOTHERAPY AS FIRST-LINE TREATMENT FOR PTSD, LARGE INTER-INDIVIDUAL DIFFERENCES IN OUTCOMES EXIST, WITH ROUGHLY 50% OF PATIENTS RESPONDING TO TREATMENT AND FEWER THAN THAT FULLY REMITTING. THIS GRANT SUPPORTED THE DEVELOPMENT OF A RESPONSE DIAGNOSTIC TEST BASED ON PRELIMINARY FINDINGS FOR A COMBINATION COGNITIVE/IMAGING MARKER RESULTING FROM CVB'S INVESTMENT IN THE COHEN VETERANS CENTER STUDY AT NYU/STANFORD. THE PROGRAM INCLUDED A CLINICAL STUDY AT TWO CENTERS OF OVER 200 SUBJECTS TO REPLICATE THE INITIAL FINDING, AND IS SEEKING QUALIFICATION VIA THE FOOD AND DRUG ADMINISTRATION ("FDA") GUIDANCE TO SUPPORT THE COMMERCIALIZATION AND/OR AVAILABILITY OF THE TEST FOR CLINICAL PRACTICE AND RESEARCH AND DEVELOPMENT. THIS STUDY COMPLETED RECRUITMENT IN DECEMBER 2019 AND SEMINAL RESULTS WHICH DEMONSTRATE THAT AN EEG BASED BIOMARKER CAN PREDICT TREATMENT RESPONSE FOR INDIVIDUALS WITH PTSD OR MDD WERE PUBLISHED IN 2020 AND 2021.IN 2023, WE HAVE COMPLETED OUR ANALYSIS OF C BIOMARKER ASSAYS ON BLOOD SAMPLES COLLECTED IN THE BEST STUDY PROGRAM TO LOOK FOR GENETIC AND INFLAMMATORY MARKERS THAT MAY BE PREDICTIVE OF RESPONSE AND/OR DISEASE AND INITIATED DISSEMINATION OF THESE RESULTS AT MULTIPLE CONFERENCES.PTSD GENETICS PROGRAM:THE PSYCHIATRIC GENETICS CONSORTIUM-PTSD WORKING GROUP - BROAD INSTITUTE COLLABORATION IS SUPPORTING THE LARGEST GLOBAL GENOME WIDE ASSOCIATION STUDY ("GWAS") OF PTSD TO DATE WITH DATA FROM OVER 200,000 INDIVIDUALS ANALYZED. THE MAIN GOAL IS TO UNCOVER THE GENETIC UNDERPINNINGS OF PTSD RISK AND PUBLISH ALL RESULTS. SEMINAL FINDINGS OF THE FIRST PTSD GENETIC RISK LOCI FROM THIS PROGRAM WERE PUBLISHED IN NATURE COMMUNICATIONS IN OCTOBER 2019.IN 2022, THE GWAS PROGRAM HAS EXPANDED TO INCLUDE OVER 350,000 INDIVIDUALS WITH TRAUMA AND 2 MILLION HEALTH CONTROLS YIELDING OVER 95 IDENTIFIED GENETIC RISK LOCI.IN 2023, THE RESULTS FOR THIS ANALYSIS WERE PUBLISHED.PRISM2 (PSYCHIATRIC RATINGS USING INTERMEDIATE STRATIFIED MARKERS 2):IN 2021, WE JOINED THE INNOVATIVE MEDICINES INITIATIVE AND EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA) AS A FUNDER AND COLLABORATOR IN THE PRISM2 STUDY PROGRAM. BUILDING ON THE SUCCESS OF INNOVATIVE RESEARCH BY THE PRISM PROJECT, THE INNOVATIVE MEDICINE INITIATIVE 2, A JOINT UNDERTAKING BETWEEN THE EU AND THE EFPIA, HAS BACKED THE PROGRAM WITH FUNDING FOR A NEW PROJECT TO EXPLORE THE UNDERLYING BIOLOGY OF ALZHEIMER'S DISEASE, SCHIZOPHRENIA AND MAJOR DEPRESSIVE DISORDER (MDD). THE NEW PRISM 2 (PSYCHIATRIC RATINGS USING INTERMEDIATE STRATIFIED MARKERS 2) PROJECT AIMS TO IDENTIFY QUANTITATIVE BIOLOGICAL FEATURES COMMON ACROSS THE DISEASES, OPENING THE POSSIBILITY OF DEVELOPING TARGETED TREATMENTS IRRESPECTIVE OF TRADITIONAL DIAGNOSIS.PRISM WAS A PAN-EUROPEAN RESEARCH PROJECT THAT RAN FROM 2016 TO 2021 AND RECEIVED $16.5 MILLION IN FUNDING FROM THE INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING, SUPPORTED BY THE EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME AND EFPIA. THE RESULTS OF PRISM CONSTITUTE THE FOUNDATION FOR THE CURRENT PRISM 2 PROJECT.THE PRISM2 PROJECT LAUNCHED IN 2022, INCLUDING PATIENT ENROLLMENT OF INDIVIDUALS WITH SCHIZOPHRENIA, DEMENTIA OR MAJOR DEPRESSION ACROSS THREE CENTERS IN EUROPE.STUDY RECRUITMENT FOR PRISM2 IS TARGETED FOR COMPLETED IN 2023.NATIONAL NORMATIVE NEUROIMAGING LIBRARY PROGRAM:CVB HAS CREATED AN IMAGING REFERENCE LIBRARY ESSENTIAL TO THE DEVELOPMENT OF EFFECTIVE CLINICAL IMAGING TOOLS FOR DIAGNOSING AND MANAGING PATIENTS WITH BRAIN DISORDERS. ADVANCED NEUROIMAGING CAN NOW DETECT MICROSCOPIC CHANGES IN BRAIN STRUCTURE CAUSED BY TRAUMA OR DISEASE. THESE ADVANCED IMAGING APPROACHES INCLUDE DIFFUSION TENSOR IMAGING ("DTI"), FUNCTIONAL CONNECTIVITY, PERFUSION WEIGHTED IMAGING, AND VOLUMETRIC IMAGING. DESPITE THEIR PROMISE, THESE ADVANCED APPROACHES ARE CURRENTLY PRIMARILY CONFINED TO RESEARCH USE. THE NUMERICAL NATURE OF THE INFORMATION THESE ADVANCED IMAGING APPROACHES YIELD IS DIFFICULT TO TRANSLATE FROM THE STUDY OF GROUPS OF INDIVIDUALS TO A SINGLE PATIENT WITHOUT A REFERENCE. THE IMAGING DATABASE IS BASED ON THE RESULTS OF A NATIONAL STUDY OF NORMATIVE INDIVIDUALS, SPONSORED BY CVB AT UNIVERSITY OF VIRGINIA, BAYLOR UNIVERSITY AND UNIVERSITY OF UTAH AND TWO MILITARY SITES.

4c	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )
	STANDARDIZED ADVANCED NEUROIMAGING SCANS ON 3,000 ADULT VOLUNTEERS, THE RESULTING IMAGING DATA, ALONG WITH DEMOGRAPHIC INFORMATION AND THE RESULTS OF NEUROCOGNITIVE ASSESSMENTS, IS FORMING A LIBRARY DOCUMENTING POPULATION VARIATION IN BRAIN STRUCTURE AND FUNCTION AS MEASURED BY THESE ADVANCED IMAGING METHODS.THROUGH THIS IMAGING DATABASE, IT IS OUR GOAL TO ADVANCE NEUROIMAGING TO DRAMATICALLY IMPROVE THE IDENTIFICATION OF AFFECTED INDIVIDUALS AND ALLOW PHYSICIANS TO OBJECTIVELY AND EFFICIENTLY DIAGNOSE CONDITIONS SUCH AS TBI, DEMENTIA AND OTHER BRAIN DISORDERS WHERE BRAIN STRUCTURE IS DETECTED VIA MRI.IN 2022, WE CONTINUED RECRUITMENT INTO THE LIBRARY, REACHING OVER 1,800 ENROLLED SUBJECTS AND ALSO ADDED BLOOD SAMPLE COLLECTION FOR NEWLY RECRUITED INDIVIDUALS. COMPUTATIONAL MODELING & DATA SCIENCES:CVB HAS ESTABLISHED AN INTRAMURAL DATA SCIENCES PROGRAM TO BUILD MACHINE-LEARNING AND ARTIFICIAL INTELLIGENCE BASED PREDICTIVE MODELS OF DISEASE. THESE PROGRAMS BUILD ON OUR ORIGINAL ORION MS BIO-MODELLING PROGRAM AND FOCUSES ON MODELS OF PTSD, TBI, PARKINSONS AND DEMENTIA AND OTHER CONDITIONS.POST-TRAUMATIC STRESS DISORDER ("PSTD") 1.0:OUR MAIN PRIORITY IS TO BUILD A MULTI-MODAL MODEL OF PTSD USING DEEPLY-PHENOTYPED COHORTS SUCH AS THE BEST STUDY AND COHEN VETERANS CENTER STUDIES. IN 2022, WE HAVE BUILT ANALYSIS PIPELINES FOR EPIGENETIC, EEG, INFLAMMATORY MARKER AND CLINICAL DATA AND WE ARE ON TRACK TO BUILD OUR FIRST MODEL BY YEAR END.PARKINSON'S PROGRESSION MARKERS INITIATIVE ("PPMI") DATA SCIENCE MODELING GROUP:EXISTING DIAGNOSES FOR COMPLEX BRAIN DISORDERS SUCH AS PARKINSON'S DISEASE FOCUS ON UNDERSTANDING CLUSTERS OF MAJOR SYMPTOMS. IN ORDER TO DRIVE PROGRESS IN THE DEVELOPMENT OF NEW TREATMENTS, IT IS IMPORTANT TO UNDERSTAND THE ROLE OF SPECIFIC BIOLOGICAL PROCESSES IN DETERMINING PATIENT OUTCOMES. IN THIS PROGRAM, WE MODEL THE MICHAEL J. FOX FOUNDATION ("MJFF") SPONSORED PARKINSON'S PROGRESSION MODEL INITIATIVE STUDY. THE STUDY HAS EVALUATED PARTICIPANTS' CLINICAL STATUS WHILE COLLECTING IMAGING, BEHAVIORAL, 'OMICS AND OTHER ASSESSMENTS LONGITUDINALLY SINCE 2010. IN OUR ALIGNED MISSIONS TO ADVANCE BRAIN HEALTH, MJFF SELECTED CVB'S DATA SCIENCE TEAM TO LEVERAGE THIS COHORT TOGETHER WITH A MULTI-DISCIPLINARY APPROACH TO QUANTITATIVELY EXPLORE, EVALUATE, AND PREDICT DISEASE TRAJECTORY, RISK FACTORS, AND SUBTYPES. GIVEN THE BREADTH AND DEPTH OF THE PPMI DATA AND RICH OPPORTUNITIES TO DEVELOP IMPACTFUL DISEASE MODELS, THE TEAM USE THEIR SUBJECT MATTER EXPERTISE ACROSS TRANSLATIONAL SCIENCE TO GENERATE INSIGHTS FROM 'OMICS, IMAGING, GENETIC AND CLINICAL DATA BY INTEGRATING TECHNIQUES ACROSS ADVANCED STATISTICS, MACHINE LEARNING, AND COMPUTATIONAL MODELING TO FACILITATE PD BIOMARKER DISCOVERY AND DEEPEN OUR UNDERSTANDING OF DISEASE PROGRESSION.MULTIPLE SCLEROSIS ("MS") 1.0:THE ORION BIONETWORKS FLAGSHIP PROGRAM SUCCESSFULLY PILOTED THE ESTABLISHMENT OF A MULTIPLE SCLEROSIS BIONETWORK COMPRISED OF ACADEMIC (NEUROSCIENCE INSTITUTE OF THE BRIGHAM AND WOMEN'S HOSPITAL), ADVOCACY (ACCELERATED CURE PROJECT FOR MS), COMPUTATIONAL (GNS HEALTHCARE, METACELL, THOMSON REUTERS), INFORMATICS (CONVERGE BY DELOITTE, RANCHO BIOSCIENCES, EXAPTIVE), AND ONLINE PATIENT COMMUNITY PARTNERS (PATIENTSLIKEME [PLM]). DE-IDENTIFIED HIPPA-COMPLIANT DATA FROM THREE DATABASES WERE CURATED AND LOADED INTO A CLOUD-BASED DATA KNOWLEDGE MANAGEMENT SYSTEM. THE INTEGRATED REPOSITORY INCLUDES 9,000 SUBJECTS WITH MS AND RELATED CONDITIONS. THE ALLIANCE DEVELOPED A ROADMAP FOR JOINT EXECUTION WITH SPECIFIC SCIENTIFIC AIMS. THE ALLIANCE HAS GENERATED MULTIPLE MODELS BASED ON THE DATA REPOSITORY USING DIFFERENT ALGORITHMIC APPROACHES: PHENOTYPIC PROGNOSTIC MODEL AND TWO MOLECULAR PROGNOSTIC MODELS.PTSD AND TBI PRECLINICAL MODELING PROGRAM:ANIMAL MODELS OF PSYCHIATRIC DISORDERS OFFER A COMPLEMENTARY RESEARCH MODALITY THAT SUPPORTS CLINICAL RESEARCH. IN ORDER TO ACHIEVE A SATISFACTORY DEGREE OF VALIDITY AND RELIABILITY, ANIMAL MODELS OF COMPLEX AND INTRICATE PSYCHIATRIC DISORDERS, SUCH AS PTSD, MUST FULFILL CERTAIN CRITERIA: PATHOGENIC PROCESSES MUST BE OBSERVABLE AND MEASURABLE, AND MUST RELIABLY REFLECT CLINICAL SYMPTOMATOLOGY, AND PHARMACOLOGICAL AGENTS THAT ARE KNOWN TO AFFECT SYMPTOMS IN HUMAN SUBJECTS, SHOULD MODULATE THESE PROCESSES. CVB HAS ESTABLISHED THE ALLIANCE FOR MODELS OF PTSD, INNOVATIVE TECHNOLOGIES AND UNIFORM PRACTICES ("AMP-IT- UP") TO SUPPORT PRECLINICAL MODEL DEVELOPMENT. MULTIPLE SUB-GRANT AWARDS COMPLETED AND PUBLISHED THEIR FINDING THIS YEAR IN SUPPORT THE MISSION OF THIS PROGRAM.PEERS - THE PLATFORM FOR THE EXCHANGE OF EXPERIMENTAL RESEARCH STANDARDS:PEERS IS A PLATFORM THAT ENABLES SHARING OF INFORMATION ON PARAMETERS THAT AFFECT THE ROBUSTNESS OF PRECLINICAL DATA. PEERS IS LIKE A WIKI ON HOW TO DESIGN, CONDUCT AND ANALYZE EXPERIMENTS TO INCREASE DATA ROBUSTNESS. PEERS ALLOWS USERS TO SEARCH FOR FACTORS AND PARAMETERS THAT ARE OF RELEVANCE TO THEIR EXPERIMENTS AND GIVES GUIDANCE AND ADVICE ON HOW TO LEVERAGE THESE FACTORS TO INCREASE THE QUALITY, ROBUSTNESS AND REPRODUCIBILITY OF RESEARCH. PEERS ALLOWS USERS TO: (1) SEARCH FOR FACTORS AND PARAMETERS THAT ARE OF RELEVANCE TO THEIR EXPERIMENTS (2) FIND RECOMMENDATIONS AND BEST PRACTICES ON EXPERIMENTAL DESIGN, EXECUTION AND DATA ANALYSIS FOR SPECIFIC IN VITRO METHODS OR IN VIVO MODELS (3) SHARE EXPERIENCES AND KNOWLEDGE TO HELP OTHERS BUILD HIGH-QUALITY, REPRODUCIBLE DATA SETS (4) CITE CONTRIBUTIONS (5) INCREASE THE QUALITY, ROBUSTNESS AND REPRODUCIBILITY OF RESEARCH.ADDRESSING SEX AS A BIOLOGICAL VARIABLE IN PRECLINICAL RESEARCH:DIFFERENCES BETWEEN MALES AND FEMALES EXTEND WELL BEYOND REPRODUCTION, WITH SIGNIFICANT IMPLICATIONS FOR HUMAN HEALTH AND DISEASE. THIS IS PARTICULARLY THE CASE IN THE FIELD OF NEUROSCIENCE, WHERE DIFFERENCES IN BASIC BIOLOGY BETWEEN MEN AND WOMEN CAN LEAD TO SEX DIFFERENCES IN THE PREVALENCE, PROGRESSION, AND RESPONSES TO TREATMENT OF MANY BRAIN DISORDERS.THIS VIDEO TRAINING SERIES WAS DEVELOPED AND LAUNCHED BY COHEN VETERANS BIOSCIENCE IN 2022, TO ENSURE THAT EARLY-STAGE RESEARCH IS CONDUCTED TO THE HIGHEST AND MOST RIGOROUS STANDARDS POSSIBLE. ONE SOLUTION IS TO ENSURE THAT THE RESEARCH COMMUNITY - INCLUDING GRADUATE STUDENTS, POSTDOCS, AND OTHER EARLY CAREER RESEARCHERS - HAVE THE TOOLS THEY NEED TO ENABLE THE IMPLEMENTATION OF BEST PRACTICES ACROSS THE EXPERIMENTAL PROCESS. THE GOAL OF THE VIDEO TRAINING SERIES, WHICH CONTAINS THREE MODULES, WAS TO PROVIDE PRACTICAL GUIDANCE TO PRECLINICAL RESEARCHERS ON HOW TO NAVIGATE THE NIH'S 2015 POLICY ON INCORPORATING SEX AS A BIOLOGICAL VARIABLE INTO THEIR CURRENT AND FUTURE RESEARCH.GLOBAL PRECLINICAL DATA FORUM:THE GLOBAL PRECLINICAL DATA FORUM ("GPDF") IS A JOINTLY SPONSORED U.S. AND EUROPEAN INITIATIVE THAT ENCOURAGES GLOBAL COLLABORATION TO ADDRESS THE CHALLENGE OF ENSURING THAT PRECLINICAL RESEARCH IS REPRODUCIBLE, ROBUST AND TRANSLATABLE TO SUPPORT DISEASE RESEARCH UTILITY FOR CLINICAL RESEARCH & DEVELOPMENT ("R&D"). IT SUPPORTS BEST RESEARCH PRACTICES, THE DEVELOPMENT AND IMPLEMENTATION OF DATA QUALITY STANDARDS, PRECLINICAL DATA & TECHNOLOGICAL PLATFORMS, AND TRAINING PROGRAMS FOR THE NEUROSCIENCE COMMUNITY WITH THE GOAL OF ENHANCING THE DATA UTILITY DERIVED FROM PRECLINICAL MODELS.THIS IS OUR FIFTH YEAR SUPPORTING, WITH THE EUROPEAN COLLEGE OF NEUROPHARMACOLOGY ("ECNP"), THE WORLD'S FIRST NEGATIVE DATA PRIZE AS AN INCENTIVE FOR PRECLINICAL RESEARCHERS TO PUBLISH "NEGATIVE DATA" RESULTS TO ENSURE ALL NEUROSCIENCE STUDIES PROPERLY ADVANCE KNOWLEDGE. THE PRIZE IS AWARDED TO THE RESEARCHER OR RESEARCH GROUP WHOSE NEUROSCIENCE STUDY BEST EXEMPLIFIES DATA WHERE THE OUTCOMES DO NOT CONFIRM THE EXPECTED RESULTS OR WORKING HYPOTHESIS. THE PRECLINICAL AWARD WAS PRESENTED DURING THE 2020 VIRTUAL ECNP CONFERENCE.IN 2023 WE CONTINUED TO AWARD THE BEST NEGATIVE PRIZE AWARDS PROGRAM TO CLINICAL RESEARCHERS WHOSE NEUROSCIENCE STUDY BEST EXEMPLIFIES DATA WHERE THE OUTCOMES DO NOT CONFIRM THE EXPECTED RESULTS OR WORKING HYPOTHESIS.EQIPD QUALITY SYSTEM:THE GPDF AND COHEN VETERANS BIOSCIENCE ARE BOTH MAJOR CONTRIBUTORS TO THE EUROPEAN UNION INNOVATIVE MEDICINE INITIATIVE-FUNDED CONSORTIUM CALLED EQIPD (EQIPD.ORG). THE EQIPD CONSORTIUM HAS DEVELOPED A NOVEL PRECLINICAL RESEARCH QUALITY SYSTEM THAT CAN BE APPLIED IN BOTH PUBLIC AND PRIVATE SECTORS AND IS FREE FOR ANYONE TO USE. THE EQIPD QUALITY SYSTEM WAS DESIGNED TO BE SUITED TO BOOST INNOVATION BY ENSURING THE GENERATION OF ROBUST AND RELIABLE PRECLINICAL DATA WHILE BEING LEAN, EFFECTIVE AND NOT BECOMING A BURDEN THAT COULD NEGATIVELY IMPACT THE FREEDOM TO EXPLORE SCIENTIFIC QUESTIONS. EQIPD DEFINES RESEARCH QUALITY AS THE EXTENT TO WHICH RESEARCH DATA ARE FIT FOR THEIR INTENDED USE.

	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )
	FITNESS, IN THIS CONTEXT, IS DEFINED BY THE STAKEHOLDERS, WHO ARE THE SCIENTISTS DIRECTLY INVOLVED IN THE RESEARCH, BUT ALSO THEIR FUNDERS, SPONSORS, PUBLISHERS, RESEARCH TOOL MANUFACTURERS AND COLLABORATION PARTNERS SUCH AS PEERS IN A MULTI-SITE RESEARCH PROJECT. THE ESSENCE OF THE EQIPD QUALITY SYSTEM IS THE SET OF 18 CORE REQUIREMENTS THAT CAN BE ADDRESSED FLEXIBLY, ACCORDING TO USER-SPECIFIC NEEDS AND FOLLOWING A USER-DEFINED TRAJECTORY. THE EQIPD QUALITY SYSTEM PROPOSES GUIDANCE ON EXPECTATIONS FOR QUALITY-RELATED MEASURES, DEFINES CRITERIA FOR ADEQUATE PROCESSES (I.E., PERFORMANCE STANDARDS) AND PROVIDES EXAMPLES OF HOW SUCH MEASURES CAN BE DEVELOPED AND IMPLEMENTED. IN 2023, EQIPD WAS AWARDED A MAJOR GRANT (ISTAND) BY THE INNOVATIVE MEDICINES INITIATIVE IN EUROPE. THERE IS CURRENTLY NO ESTABLISHED FRAMEWORK READILY AVAILABLE OUTSIDE OF SELECTED COMPANIES AND RESEARCH ORGANIZATIONS THAT APPLY INTERNALLY-DEVELOPED STANDARDS AND CRITERIA TO SUPPORT ADEQUATE RESEARCH RIGOR THAT IS COMMENSURATE WITH THE PURPOSE AND APPROPRIATELY ACHIEVABLE. THE GRANT PROGRAM WILL ESTABLISH AND TEST SUCH A FRAMEWORK TO SUPPORT THE PROCESSES OF GENERATING AND REPORTING NONREGULATED RESEARCH RESULTS, AND TO SYSTEMATIZE DECISION-MAKING BASED ON SUCH RESULTS. IT COULD BE APPLIED TO NONREGULATED RESEARCH IN ANY DOMAIN (I.E., RESEARCH NOT CONDUCTED UNDER GOOD PRACTICE GXP STANDARDS SUCH AS GLP), INCLUDING THE DEVELOPMENT OF BIOMARKERS.POLICY & ADVOCACY INITIATIVES:WE ARE COMMITTED TO ADVOCATING FOR POLICY REFORMS AT THE FEDERAL LEVEL THAT BUILD UPON EVIDENCE-BASED PRECISION MEDICINE APPROACHES AND HAVE THE POWER TO BRING NEW SOLUTIONS FOR PTSD AND TBI IN YEARS, NOT DECADES. AS PART OF OUR ADVOCACY EFFORTS, WE CO-FOUNDED THE COALITION TO HEAL INVISIBLE WOUNDS (THE "COALITION"), A COLLABORATIVE INITIATIVE AIMED AT ADVOCATING FOR POLICY REFORMS TO WIDEN AND EXPEDITE THE PIPELINE FOR NEW THERAPIES AND DIAGNOSTICS FOR PTSD AND TBI - WHICH CAN BOTH DRASTICALLY INCREASE THE RISK OF SUICIDE AMONG VETERANS. IN 2023, WE CONTINUE TO GROW MEMBERSHIP IN THE ALLIANCE AS WELL AS CONTRIBUTE TO THE ADVANCEMENT OF SEMINAL LEGISLATION TO SUPPORT VETERANS AND BRAIN RESEARCH.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses13,585,394

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)				(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(A) Name and title
(1) MAGALI HAAS MD PHD...................................................................... CEO & PRESIDENT	40.00 .................	X	X			547,435	0	18,300
(2) THERESA FRANGIOSA...................................................................... SECRETARY	9.00 .................	X	X			0	0	0
(3) MICHAEL SULLIVAN...................................................................... TREASURER	1.00 .................	X	X			0	0	0
(4) DAVID BIONDI...................................................................... BOARD MEMBER	1.00 .................	X				0	0	0
(5) DAVE DEMARCO...................................................................... BOARD MEMBER	1.00 .................	X				0	0	0
(6) LEE LANCASHIRE...................................................................... CHIEF INFORMATION OFFICER	40.00 .................			X		310,941	0	57,367
(7) ALLYSON GAGE PHD...................................................................... CHIEF MEDICAL OFFICER	40.00 .................			X		481,736	0	22,635
(8) AMANDA NICOLE HARMON...................................................................... CHIEF OPERATIONS OFFICER	40.00 .................			X		364,717	0	36,449
(9) EVGENY RAKHMATULIN...................................................................... CHIEF TECHNOLOGY OFFICER	40.00 .................			X		305,572	0	38,944
(10) PETER HOEHN...................................................................... EXECUTIVE VP, MARKING STRATEGY, DEVELOP, & IMPACT	40.00 .................			X		183,750	0	0
(11) LAUREN GOLDSMITH...................................................................... SENIOR DIRECTOR, CONTRACTS	40.00 .................				X	229,944	0	22,610
(12) MARK ZERVAS...................................................................... DEPUTY DIRECTOR, TRANSLATI	40.00 .................				X	217,246	0	36,101
(13) MARYAN ZIRKLE...................................................................... EXECUTIVE DIRECTOR, BRAINC	40.00 .................				X	281,688	0	25,337
(14) RENEE DAVIS...................................................................... EXECUTIVE DIRECTOR, DEVELO	40.00 .................				X	208,434	0	18,344
(15) ANDREW THOMPSON...................................................................... ASSOCIATE DIRECTOR, DATA SCIENCE	40.00 .................				X	159,579	0	18,005

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	3,291,042	0	294,092

1a	Federated campaigns..		1a
b	Membership dues..		1b
c	Fundraising events..		1c
d	Related organizations		1d
e	Government grants (contributions)		1e

f	All other contributions, gifts, grants, and similar amounts not included above		1f	10,755,381

g	Noncash contributions included in lines 1a - 1f:$		1g

h Total. Add lines 1a-1f.......		10,755,381

		Business Code
2a
b
c
d
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....

3 Investment income (including dividends, interest, and othersimilar amounts) ......			223,966			223,966
4 Income from investment of tax-exempt bond proceeds
5 Royalties...........
		(ii) Personal	(i) Real
6a	Gross rents			6a
b	Less: rental expenses			6b
c	Rental income or (loss)			6c
d	Net rental income or (loss).......
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory			7a
b	Less: cost or other basis and sales expenses			7b
c	Gain or (loss)			7c
d	Net gain or (loss).........
8a	Gross income from fundraising events (not including $ of contributions reported on line 1c). See Part IV, line 18 ....
			8a
b	Less: direct expenses ...		8b
c	Net income or (loss) from fundraising events..
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a
b	Less: direct expenses ...		9b
c	Net income or (loss) from gaming activities..
10a	Gross sales of inventory, less returns and allowances ..
			10a
b	Less: cost of goods sold ..		10b
c	Net income or (loss) from sales of inventory..
Business Code			Miscellaneous Revenue
11a	GRANT REFUNDS		900099	326,982	326,982
b	OTHER REFUNDS		900099	37,205	37,205
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			364,187
12	Total revenue. See instructions.....			11,343,534	364,187	0	223,966

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	108,171	108,171
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	90,026	90,026
4	Benefits paid to or for members .......
5	Compensation of current officers, directors, trustees, and key employees ...........	2,748,100	2,461,672	136,427	150,001
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........
7	Other salaries and wages........	3,171,915	2,798,978	178,570	194,367
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	183,596	164,976	8,912	9,708
9	Other employee benefits .......	339,311	304,762	16,524	18,025
10	Payroll taxes ...........	316,822	284,374	15,503	16,945
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	317,900	229,420	88,480
c	Accounting ...........	414,998	6,320	408,678
d	Lobbying ...........	120,000	120,000
e	Professional fundraising services. See Part IV, line 17
f	Investment management fees ......
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	4,827,370	4,584,048	222,134	21,188
12	Advertising and promotion ....
13	Office expenses .......	496,972	319,644	169,622	7,706
14	Information technology ......	518,142	510,664	5,049	2,429
15	Royalties ..
16	Occupancy ...........	524,989	500,366	24,560	63
17	Travel ............	461,481	441,230	17,090	3,161
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .
19	Conferences, conventions, and meetings ....	251,896	249,121	2,775
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization ..	344,987	340,599	2,097	2,291
23	Insurance ...	104,690	71,023	29,435	4,232
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a
b
c
d
e	All other expenses
25	Total functional expenses. Add lines 1 through 24e	15,341,366	13,585,394	1,325,856	430,116
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

1	Cash–non-interest-bearing ........			999,648	1	828,606
2	Savings and temporary cash investments .........			3,831,713	2	5,471,810
3	Pledges and grants receivable, net ......			8,295,108	3	1,762,522
4	Accounts receivable, net .............			21,300	4
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
					6
7	Notes and loans receivable, net ...........				7
8	Inventories for sale or use ............				8
9	Prepaid expenses and deferred charges ......			123,073	9	98,344
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	2,508,484
b	Less: accumulated depreciation	10b	541,027	1,432,920	10c	1,967,457
11	Investments—publicly traded securities .				11
12	Investments—other securities. See Part IV, line 11 .....				12
13	Investments—program-related. See Part IV, line 11 ..				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........			883,589	15	1,614,659
16	Total assets. Add lines 1 through 15 (must equal line 33)...			15,587,351	16	11,743,398

17	Accounts payable and accrued expenses .....	2,682,753	17	1,818,611
18	Grants payable ...	137,446	18
19	Deferred revenue .........	740,285	19	740,285
20	Tax-exempt bond liabilities .........		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D		21
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
			22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ..		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	139,342	25	1,294,809
26	Total liabilities. Add lines 17 through 25..	3,699,826	26	3,853,705

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	7,257,190	27	5,480,842
28	Net assets with donor restrictions ...........	4,630,335	28	2,408,851
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	11,887,525	32	7,889,693
33	Total liabilities and net assets/fund balances ........	15,587,351	33	11,743,398

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No